

01/27/00  
jc685 U.S. PTO

PATENT

Attorney's Docket Number: 3495.0111-11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Prior Application: Art Unit: 1633  
Examiner: S. Kaushal

jc571 U.S. PTO  
09/492697  
01/27/00

SIR: This is a request for filing a

■ Continuation Application under 37 C.F.R. § 1.53(b) of pending prior application Serial No. 09/244,130 filed February 4, 1999, which is a Division of application Serial No. 09/119,024, filed July 20, 1998, which is a Continuation of application Serial No. 08/336,241, filed November 7, 1994, which is a CIP of application Serial No. 07/971,160, filed November 5, 1992, which is a CIP of application Serial No. 07/879,689, filed May 5, 1992 of Bernard DUJON et al. for NUCLEOTIDE SEQUENCE ENCODING THE ENZYME I-SceI AND THE USES THEREOF

1. ■ Enclosed is a complete copy of the prior application including the oath or Declaration and drawings, if any, as originally filed. I hereby verify that the attached papers are a true copy of prior application Serial No. 08/336,241 as originally filed on November 7, 1994.
2. □ Enclosed is a substitute specification under 37 C.F.R. § 1.125.
3. ■ Cancel Claims 2-22.
4. ■ A Preliminary Amendment is enclosed.
5. ■ The filing fee is calculated on the basis of the claims existing in the prior application as amended at 3 and 4 above.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, D. C. 20005  
202-408-4000

Basic Application Filing Fee					\$690	\$ 690.00
	Number of Claims		Basic	Extra Claims		
Total Claims	42	-	20	22	x \$18	396.00
Independent Claims	3	-	3	0	x \$78	
[ X ] Presentation of Multiple Dep. Claim(s)					+\$260	260.00
					Subtotal	\$ 1346.00
					Reduction by 1/2 if small entity	-
					TOTAL APPLICATION FILING FEE	\$ 1346.00

6. ■ A check in the amount of \$ 1,346.00 to cover the filing fee is enclosed.
7. ■ The Commissioner is hereby authorized to charge any fees which may be required including fees due under 37 C.F.R. § 1.16 and any other fees due under 37 C.F.R. § 1.17, or credit any overpayment during the pendency of this application to Deposit Account No. 06-0916.
8. ■ Amend the specification by inserting before the first line, the sentence:  
  
 --This is a Continuation of application Serial No. 09/244,130 filed February 4, 1999, which is a Division of application Serial No. 09/119,024, filed July 20, 1998, now U.S. Patent No. 5,948,678, which is a Continuation of application Serial No. 08/336,241, filed November 7, 1994, now U.S. Patent No. 5,792,632, which is a CIP of application Serial No. 07/971,160, filed November 5, 1992, now U.S. Patent No. 5,474,896, which is a CIP of application Serial No. 07/879,689, filed May 5, 1992, now abandoned, all of which are incorporated herein by reference.--
9. □ New formal drawings are enclosed.
10. ■ The prior application is assigned of record to: Institut Pasteur at Reel 7450, Frame 0500, and Universite Pierre et Marie Curie at Reel 7450, Frame 0446.
11. □ Priority of application Serial No. \_\_\_\_\_, filed on \_\_\_\_\_ in \_\_\_\_\_ (country) is claimed under 35 U.S.C. § 119. A certified copy  
 □ is enclosed or □ is on file in the prior application.

09/244,130

LAW OFFICES

FINNEGAN, HENDERSON,  
 FARABOW, GARRETT,  
 & DUNNER, L.L.P.  
 1300 I STREET, N. W.  
 WASHINGTON, D. C. 20005  
 202-408-4000

12. ☐ A verified statement claiming small entity status

☐ is enclosed or ☐ is on file in the prior application.

13. ■ The power of attorney in the prior application is to at least one of the following: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilley, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewris, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Roger D. Taylor, Reg. 28,992; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 32,013; Andrew Chanhon Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neth, Reg. No. 36,363; Gerson S. Panitch, Reg. No. 33,751; Cheri M. Taylor, Reg. No. 33,216; Charles E. Van Horn, Reg. No. 40,266; Linda A. Wadler, Reg. No. 33,218; Jeffrey A. Berkowitz, Reg. No. 36,743; Michael R. Kelly, Reg. No. 33, 921; James B. Monroe, Reg. No. 33,971; Doris Johnson Hines, Reg. No. 34,629; Allen R. Jensen, Reg. No. 28,224; Lori Ann Johnson, Reg. No. 34,498; and David A. Manspeizer, Reg. No. 37,540.

14. ■ The power appears in the original declaration of the prior application.

15. ☐ Since the power does not appear in the original declaration, a copy of the power in the prior application is enclosed.

00427 46326460

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, D. C. 20005  
202-408-4000

16. ■ Please address all correspondence to FINNEGAN, HENDERSON, FARABOW, GARRETT and DUNNER, L.L.P., 1300 I Street, N.W., Washington, D.C. 20005-3315.

17. □ Recognize as associate attorney \_\_\_\_\_  
\_\_\_\_\_  
(name, address & Reg. No.)

18. □ Also enclosed is \_\_\_\_\_  
\_\_\_\_\_

PETITION FOR EXTENSION. If any extension of time is necessary for the filing of this application, including any extension in the parent application, Serial No. 09/244,130, filed February 4, 1999, for the purpose of maintaining copendency between the parent application and this application, and such extension has not otherwise been requested, such an extension is hereby requested, and the Commissioner is authorized to charge necessary fees for such an extension to our Deposit Account No. 06-0916. A duplicate copy of this paper is enclosed for use in charging the deposit account.

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By: *Kenneth J. Meyers* (Reg. No. 34,872)  
For: Kenneth J. Meyers  
Reg. No.: 25,146

Date: January 27, 2000

09/244,130 "01300"

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, D. C. 20005  
202-408-4000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Bernard DUJON et al. )  
)  
Serial Number: Unassigned )  
(Continuation of Serial No.: 09/244,130) ) Group Art Unit: Unassigned  
)  
Filed: January 27, 2000 ) Examiner: Unassigned

For: NUCLEOTIDE SEQUENCE ENCODING  
THE ENZYME I-SCEI AND THE USES THEREOF

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**PRELIMINARY AMENDMENT**

Prior to the examination of the above application, please amend this application as follows:

**IN THE SPECIFICATION:**

On page 4, line 12, after "Dujon et al., 1985;" insert --(ref. 7 and ref. A4);--; and  
line 13, after "Colleaux et al., 1986;" insert --(ref. 8)--.

Page 5, second line from bottom, after "TAA", insert --(SEQ ID NO:1)--; and  
last line, after "\*" insert --(SEQ ID NO:2)--.

Page 7, line 5, after "gene." insert --(SEQ ID NOS: 3 and 4)--;  
line 8, after "enzyme." insert --(SEQ ID NOS: 5 and 2)--;  
line 11, after "recognition." insert --(SEQ ID NOS: 6, 7, and 8)--;  
line 15, after "box." insert --(SEQ ID NOS: 9 through 16)--;  
line 17, after "I-Sce I." insert --(SEQ ID NO:2)--;

004270 2636460

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, D. C. 20005  
202-408-4000

Continuation of Serial No.: 09/244,130

line 19, after "endonucleases." insert --(SEQ ID NOS:17 through 44)--; and

line 28, after "pAF100." insert --(SEQ ID NOS:45 through 50)--.

Page 10, line 21, delete "HR" and insert therefor --homologous recombination (HR)--.

Page 13, line 18, delete "SSA" and insert therefor --single-strand annealing (SSA)--.

Page 14, line 22, delete "a)" and insert therefor --a1)--.

Page 18, substitute the following for the last two lines:

--5' TAGGGATAA ↓ CAGGGTAAT 3' (SEQ ID NO:51)

3' ATCCC ↑ TATTGTCCCATTA 5' (SEQ ID NO:52)--.

Page 48, line 2, delete "'polybrain'" and insert therefor --polybrene (hexadimethrine bromide)--.

Page 72, line 3, delete "[11]" and insert therefor --[11B]--.

Page 72, line 23, delete "[13]" and insert therefor --[13B]--.

Page 72, line 27, delete "[12]" and insert therefor --[12B]--.

Page 80, line 14, delete "[29]" and insert therefor --[29B]--.

Page 91, line 24, delete "Varmus, H. and Brown, P. 1989. Retroviruses" and insert therefor --Varmus, H. and Brown, P., Retroviruses *in* Mobile DNA, 58-108 (Douglas E. Berg and Martha H. Howe eds., 1989).--.

After making the above amendments, please move pages 50-58 and insert these pages after page 88 and before page 89 of the application. Then please renumber the pages as follows:

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, D. C. 20005  
202-408-4000

Continuation of Serial No.: 09/244,130

Renumber pages 50-58 as pages 80-88, respectively; and renumber pages 59-88 as pages 50-79, respectively.

After page 93, and before page 94, please insert the attached pages titled "SEQUENCE LISTING".

On pages 89-93, renumber references "1" through "37" to read --1B-- through --37B--.

IN THE CLAIMS:

Please cancel claim 1.

Please add the following new claims:

--23. A recombinant mammalian or plant chromosome comprising an endonuclease site selected from the group consisting of HO endonuclease and Group I intron encoded endonuclease sites.

24. The recombinant chromosome of claim 23, wherein said endonuclease site is a Group I intron encoded endonuclease site.

25. The recombinant chromosome of claim 24, wherein said endonuclease site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class III I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites.

26. The recombinant chromosome of claim 25, wherein said endonuclease site is a Class I I-endonuclease site.

09/244,130

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, D. C. 20005  
202-408-4000

Continuation of Serial No.: 09/244,130

27. The recombinant chromosome of claim 26, wherein said endonuclease site is selected from the group consisting of I-SceI, I-SceIV, I-Csml, and I-PanI sites.

28. The recombinant chromosome of claim 27, wherein said endonuclease site is an I-SceI site.

29. The recombinant chromosome of any of claims 23-28, wherein said chromosome is a mouse chromosome.

30. A recombinant mammalian or plant cell comprising a recombinant chromosome comprising an endonuclease site selected from the group consisting of HO endonuclease and Group I intron encoded endonuclease sites.

31. The recombinant cell of claim 30, wherein said endonuclease site is a Group I intron encoded endonuclease site.

32. The recombinant cell of claim 31, wherein said endonuclease site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class III I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites.

33. The recombinant cell of claim 32, wherein said endonuclease site is a Class I I-endonuclease site.

34. The recombinant cell of claim 33, wherein said endonuclease site is selected from the group consisting of I-SceI, I-SceIV, I-Csml, and I-PanI sites.

002670-2696450

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, D. C. 20005  
202-408-4000

35. The recombinant cell of claim 34, wherein said endonuclease site is an I-SceI site.

36. The recombinant cell of any of claims 30-35, wherein said cell is a mouse cell.

37. The recombinant cell of claim 36, wherein said cell is a mouse stem cell.

38. A retroviral vector comprising an endonuclease site selected from the group consisting of HO endonuclease and Group I intron encoded endonuclease sites.

39. The retroviral vector of claim 38, wherein said endonuclease site is a Group I intron encoded endonuclease site.

40. The retroviral vector of claim 39, wherein said endonuclease site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class III I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites.

41. The retroviral vector of claim 40, wherein said endonuclease site is a Class I I-endonuclease site.

42. The retroviral vector of claim 41, wherein said endonuclease site is selected from the group consisting of I-SceI, I-SceIV, I-Csml, and I-PanI sites.

43. The retroviral vector of claim 42, wherein said endonuclease site is an I-SceI site.

09/244,130

44. The retroviral vector of any of claims 38-43, wherein said retroviral vector is a Moloney Murine Leukemia Virus vector.--

**REMARKS**

This amendment is intended to correct typographical errors, incomplete citations, and ambiguous references to listed citations in the specification. Support for this amendment is found throughout the specification. New claims 23-44 find support in the specification and original claims, for example as follows:

<u>New Claim</u>	<u>Supported in Specification at:</u>
23-44	Page 1, lines 9-16; page 3, line 15, through page 4, line 23; page 6, lines 12-23; page 26, line 5, through page 27, line 25; page 29, line 16, through page 30, line 20; page 35, line 16, through page 36, line 13; page 36, line 22, through page 38, line 16; page 38, lines 9-16; page 47, line 3, through page 48, line 10; page 49, lines 8-12; Fig. 6.; and Fig. 13.

*Continuation of Serial No.: 09/244,130*

24, 31, and 39	Page 26, line 5, through page 27, line 25; and Fig. 6.
25, 32, and 40	Page 27, lines 3-25; and Fig. 6.
26, 33, and 41	Page 27, lines 3-13; and Fig. 6.
27, 34, and 42	Page 27, lines 3-10; and Fig. 6.
28, 35, and 43	Page 27, lines 3-7; Fig. 6; and Fig. 13.
29 and 36	Page 38, lines 9-16; and page 47, line 3, through page 48, line 10.
44	Page 38, lines 9-16; and page 47, line 3, through page 48, line 10; and Fig. 13.

Accordingly, no new matter is entered by way of this amendment and entry is respectfully requested.

Applicants submit herewith a Sequence Listing and have amended the specification to conform with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicants request the use of the computer-readable copy submitted in U.S. application Serial No.

Continuation of Serial No.: 09/244,130

08/336,241 filed November 7, 1994, now U.S. Patent No. 5,792,632 issued August 11, 1998.

I hereby state that the contents of the enclosed Sequence Listing and the computer-readable copy of the Sequence Listing in U.S. application Serial No. 08/336,241 filed November 7, 1994, now U.S. Patent No. 5,792,632 issued August 11, 1998, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

I further state that the submission, filed in accordance with 37 C.F.R. § 1.821(g) does not contain new matter.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER L.L.P.

By: *Kenneth J. Meyers* (Reg. No. 34,872)  
for: Kenneth J. Meyers  
Reg. No. 25,146

Dated: January 27, 2000

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, D. C. 20005  
202-408-4000



Atty. Docket: 03495-0111-03000

UNITED STATES PATENT APPLICATION

OF

ANDRE CHOULIKA, ARNAUD PERRIN,  
BERNARD DUJON and JEAN-FRANCOIS NICOLAS

FOR

NUCLEOTIDE SEQUENCE ENCODING THE ENZYME I-SceI AND  
THE USES THEREOF

00495-0111-03000

for studying the action of genes, and for studying the intricate interaction of cells in the immune system. The whole animal is the ultimate assay system for manipulated genes, which direct complex biological processes.

Transgenic animals can provide a general assay for functionally dissecting DNA sequences responsible for tissue specific or developmental regulation of a variety of genes. In addition, transgenic animals provide useful vehicles for expressing recombinant proteins and for generating precise animal models of human genetic disorders.

For a general discussion of gene cloning and expression in animals and animal cells, see Old and Primrose, "Principles of Gene Manipulation," Blackwell Scientific Publications, London (1989), page 255 *et seq.*

Transgenic lines, which have a predisposition to specific diseases and genetic disorders, are of great value in the investigation of the events leading to these states. It is well known that the efficacy of treatment of a genetic disorder may be dependent on identification of the gene defect that is the primary cause of the disorder. The discovery of effective treatments can be expedited by providing an animal model that will lead to the disease or disorder, which will enable the study of the efficacy, safety, and mode of action of treatment protocols, such as genetic recombination.

One of the key issues in understanding genetic recombination is the nature of the initiation step. Studies of homologous recombination in bacteria and fungi have led to the proposal of two types of initiation mechanisms. In the first

model, a single-strand nick initiates strand assimilation and branch migration (Meselson and Radding 1975). Alternatively, a double-strand break may occur, followed by a repair mechanism that uses an uncleaved homologous sequence as a template (Resnick and Martin 1976). This latter model has gained support from the fact that integrative transformation in yeast is dramatically increased when the transforming plasmid is linearized in the region of chromosomal homology (Orr-Weaver, Szostak and Rothstein 1981) and from the direct observation of a double-strand break during mating type interconversion of yeast (Strathern et al. 1982). Recently, double-strand breaks have also been characterized during normal yeast meiotic recombination (Sun et al. 1989; Alani, Padmore and Kleckner 1990).

Several double-strand endonuclease activities have been characterized in yeast: HO and intron encoded endonucleases are associated with homologous recombination functions, while others still have unknown genetic functions (Endo-SceI, Endo-SceII) (Shibata et al. 1984; Morishima et al. 1990). The HO site-specific endonuclease initiates mating-type interconversion by making a double-strand break near the YZ junction of *MAT* (Kostriken et al. 1983). The break is subsequently repaired using the intact *HML* or *HMR* sequences and resulting in ectopic gene conversion. The HO recognition site is a degenerate 24 bp non-symmetrical sequence (Nickoloff, Chen, and Heffron 1986; Nickoloff, Singer and Heffron 1990). This sequence has been used as a "recombinator" in artificial constructs to promote intra- and

0049269 012700

intermolecular mitotic and meiotic recombination (Nickoloff, Chen and Heffron, 1986; Kolodkin, Klar and Stahl 1986; Ray et al. 1988, Rudin and Haber, 1988; Rudin, Sugarman, and Haber 1989).

The two-site specific endonucleases, I-SceI (Jacquier and Dujon 1985) and I-SceII (Delahodde et al. 1989; Wenzlau et al. 1989), that are responsible for intron mobility in mitochondria, initiate a gene conversion that resembles the HO-induced conversion (see Dujon 1989 for review). I-SceI, which is encoded by the optional intron Sc LSU.1 of the 21S rRNA gene, initiates a double-strand break at the intron insertion site (Macreadie et al. 1985; Dujon et al. 1985; Colleaux et al. 1986). The recognition site of I-SceI extends over an 18 bp non-symmetrical sequence (Colleaux et al. 1988). Although the two proteins are not obviously related by their structure (HO is 586 amino acids long while I-SceI is 235 amino acids long), they both generate 4 bp staggered cuts with 3'OH overhangs within their respective recognition sites. It has been found that a mitochondrial intron-encoded endonuclease, transcribed in the nucleus and translated in the cytoplasm, generates a double-strand break at a nuclear site. The repair events induced by I-SceI are identical to those initiated by HO.

In summary, there exists a need in the art for reagents and methods for providing transgenic animal models of human diseases and genetic disorders. The reagents can be based on the restriction enzyme I-SceI and the gene encoding this enzyme. In particular, there exists a need for reagents and

0049369 03200

methods for replacing a natural gene with another gene that is capable of alleviating the disease or genetic disorder.

# SUMMARY OF THE INVENTION

Accordingly, this invention aids in fulfilling these needs in the art. Specifically, this invention relates to an isolated DNA encoding the enzyme I-SceI. The DNA has the following nucleotide sequence:

```

                ATG CAT ATG AAA AAC ATC AAA AAA AAC CAG GTA ATG 2670
                M   H   M   K   N   I   K   K   N   Q   V   M   12

2671 AAC CTC GGT CCG AAC TCT AAA CTG CTG AAA GAA TAC AAA TCC CAG CTG ATC GAA CTG AAC 2710
   13 N   L   G   P   N   S   K   L   L   K   E   Y   K   S   Q   L   I   E   L   N   32

2731 ATC GAA CAG TTC GAA GCA GGT ATC GGT CTG ATC CTG GGT GAT GCT TAC ATC CGT TCT CGT 2790
   33 I   E   Q   F   E   A   G   I   G   L   I   L   G   D   A   Y   I   R   S   R   52

2791 GAT GAA GGT AAA ACC TAC TGT ATG CAG TTC GAG TGG AAA AAC AAA GCA TAC ATG GAC CAC 2850
   53 D   E   G   K   T   Y   C   M   Q   F   E   W   K   N   K   A   Y   M   D   H   72

2851 GTA TGT CTG CTG TAC GAT CAG TGG GTA CTG TCC CCG CCG CAC AAA AAA GAA CGT GTT AAC 2910
   73 V   C   L   L   Y   D   Q   W   V   L   S   P   P   H   K   K   E   R   V   N   92

2911 CAC CTG GGT AAC CTG GTA ATC ACC TGG GGC GCC CAG ACT TTC AAA CAC CAA GCT TTC AAC 2970
   93 H   L   G   N   L   V   I   T   W   G   A   Q   T   F   K   H   Q   A   F   N   112

2971 AAA CTG GCT AAC CTG TTC ATC GTT AAC AAC AAA AAA ACC ATC CCG AAC AAC CTG GTT GAA 3030
  113 K   L   A   N   L   F   I   V   N   N   K   K   T   I   P   N   N   L   V   E   132

3031 AAC TAC CTG ACC CCG ATG TCT CTG GCA TAC TGG TTC ATG GAT GAT GGT GGT AAA TGG GAT 3090
  133 N   Y   L   T   P   M   S   L   A   Y   W   F   M   D   D   G   G   K   W   D   152

3091 TAC AAC AAA AAC TCT ACC AAC AAA TCG ATC GTA CTG AAC ACC CAG TCT TTC ACT TTC GAA 3150
  153 Y   N   K   N   S   T   N   K   S   I   V   L   N   T   Q   S   F   T   F   E   172

3151 GAA GTA GAA TAC CTG GTT AAG GGT CTG CGT AAC AAA TTC CAA CTG AAC TGT TAC GTA AAA 3210
  173 E   V   E   Y   L   V   K   G   L   R   N   K   F   Q   L   N   C   Y   V   K   192

3211 ATC AAC AAA AAC AAA CCG ATC ATC TAC ATC GAT TCT ATG TCT TAC CTG ATC TTC TAC AAC 3270
  193 I   N   K   N   K   P   I   I   Y   I   D   S   M   S   Y   L   I   F   Y   N   212

3271 CTG ATC AAA CCG TAC CTG ATC CCG CAG ATG ATG TAC AAA CTG CCG AAC ACT ATC TCC TCC 3330
  213 L   I   K   P   Y   L   I   P   Q   M   M   Y   K   L   P   N   T   I   S   S   232

3331 GAA ACT TTC CTG AAA TAA
     233 E   T   F   L   K   *

```

00493697 012700

This invention also relates to a DNA sequence comprising a promoter operatively linked to the DNA sequence of the invention encoding the enzyme I-SceI.

This invention further relates to an isolated RNA complementary to the DNA sequence of the invention encoding the enzyme I-SceI and to the other DNA sequences described herein.

In another embodiment of the invention, a vector is provided. The vector comprises a plasmid, bacteriophage, or cosmid vector containing the DNA sequence of the invention encoding the enzyme I-SceI.

In addition, this invention relates to *E. coli* or eukaryotic cells transformed with a vector of the invention.

Also, this invention relates to transgenic animals containing the DNA sequence encoding the enzyme I-SceI and cell lines cultured from cells of the transgenic animals.

In addition, this invention relates to a transgenic organism in which at least one restriction site for the enzyme I-SceI has been inserted in a chromosome of the organism.

Further, this invention relates to a method of genetically mapping a eukaryotic genome using the enzyme I-SceI.

This invention also relates to a method for in vivo site directed recombination in an organism using the enzyme I-SceI.

002270 2592460

# BRIEF DESCRIPTION OF THE DRAWINGS

This invention will be more fully described with reference to the drawings in which:

**Figure 1** depicts the universal code equivalent of the mitochondrial I-SceI gene.

**Figure 2** depicts the nucleotide sequence of the invention encoding the enzyme I-SceI and the amino acid sequence of the natural I-SceI enzyme.

**Figure 3** depicts the I-SceI recognition sequence and indicates possible base mutations in the recognition site and the effect of such mutations on stringency of recognition.

**Figure 4** is the nucleotide sequence and deduced amino acid sequence of a region of plasmid pSCM525. The nucleotide sequence of the invention encoding the enzyme I-SceI is enclosed in the box.

**Figure 5** depicts variations around the amino acid sequence of the enzyme I-SceI.

**Figure 6** shows Group I intron encoding endonucleases and related endonucleases.

**Figure 7** depicts yeast expression vectors containing the synthetic gene for I-SceI.

**Figure 8** depicts the mammalian expression vector PRSV I-SceI.

**Figure 9** is a restriction map of the plasmid pAF100. (See also YEAST, 6:521-534, 1990, which is relied upon and incorporated by reference herein).

**Figures 10A and 10B** show the nucleotide sequence and restriction sites of regions of the plasmid pAF100.

0049337-03300

**Figure 11** depicts an insertion vector pTSM $\omega$ , pTKM $\omega$ , and pTTc $\omega$  containing the I-SceI site for *E. coli* and other bacteria.

**Figure 12** depicts an insertion vector pTYW6 containing the I-SceI site for yeast.

**Figure 13** depicts an insertion vector PMLV LTR SAPLZ containing the I-SceI site for mammalian cells.

**Figure 14** depicts a set of seven transgenic yeast strains cleaved by I-SceI. Chromosomes from FY1679 (control) and from seven transgenic yeast strains with I-SceI sites inserted at various positions along chromosome XI were treated with I-SceI. DNA was electrophoresed on 1% agarose (SeaKem) gel in 0.25 X TBE buffer at 130 V and 12°C on a Rotaphor apparatus (Biometra) for 70 hrs using 100 sec to 40 sec decreasing pulse times. (A) DNA was stained with ethidium bromide (0.2µg/ml) and transferred to a Hybond N (Amersham) membrane for hybridization. (B) <sup>32</sup>P labelled cosmid pUKG040 which hybridizes with the shortest fragment of the set was used as a probe. Positions of chromosome XI and shorter chromosomes are indicated.

**Figure 15** depicts the rationale of the nested chromosomal fragmentation strategy for genetic mapping. (A) Positions of *I*-SceI sites are placed on the map, irrespective of the left/right orientation (shorter fragments are arbitrarily placed on the left). Fragment sizes as measured from PFGE (Fig. 14A) are indicated in kb (note that the sum of the two fragment sizes varies slightly due to the limit of precision of each measurement). (B) Hybridization with the



probe that hybridizes the shortest fragment of the set determines the orientation of each fragment (see Fig. 14B). Fragments that hybridize with the probe (full lines) have been placed arbitrarily to the left. (C) Transgenic yeast strains have been ordered with increasing sizes of hybridizing chromosome fragments. (D) Deduced *I*-SceI map with minimal and maximal size of intervals indicated in kb (variations in some intervals are due to limitations of PFGE measurements). (E) Chromosome subfragments are used as probes to assign each cosmid clone to a given map interval or across a given *I*-SceI site.

**Figure 16** depicts mapping of the *I*-SceI sites of transgenic yeast strains by hybridization with left end and right end probes of chromosome XI. Chromosomes from FY1679 (control) and the seven transgenic yeast strains were digested with *I*-SceI. Transgenic strains were placed in order as explained in Fig. 15. Electrophoresis conditions were as in Fig. 14. <sup>32</sup>P labelled cosmids pUKG040 and pUKG066 were used as left end and right end probes, respectively.

**Figure 17** depicts mapping of a cosmid collection using the nested chromosomal fragments as probes. Cosmid DNAs were digested with EcoRI and electrophoresed on 0.9% agarose (SeaKem) gel at 1.5 V/cm for 14 hrs, stained with ethidium bromide and transferred to a Hybond N membrane. Cosmids were placed in order from previous hybridizations to help visualize the strategy. Hybridizations were carried out serially on three identical membranes using left end nested chromosome fragments purified on PFGE (see Fig. 16) as

0049267 012700

probes. A: ethidium bromide staining (ladder is the BRL "1kb ladder"), B: membrane #1, probe: Left tel to A302 site, C: membrane #1, probe: Left tel to M57 site, D: membrane #2, probe: Left tel to H81 site, E: membrane #2, probe: Left tel to T62 site, F: membrane #3, probe: Left tel to G41 site, G: membrane #3, probe: Left tel to D304 site, H: membrane #3, probe: entire chromosome XI.

**Figure 18** depicts a map of the yeast chromosome XI as determined from the nested chromosomal fragmentation strategy. The chromosome is divided into eight intervals (with sizes indicated in kb, see Fig. 15D) separated by seven *I-SceI* sites (E40, A302 ...). Cosmid clones falling either within intervals or across a given *I-SceI* site are listed below intervals or below interval boundaries, respectively. Cosmid clones that hybridize with selected genes used as probes are indicated by letters (a-i). They localize the gene with respect to the *I-SceI* map and allow comparison with the genetic map (top).

**Figure 19** depicts diagrams of successful site directed homologous recombination experiments performed in yeast.

**Figure 20.** Experimental design for the detection of HR induced by *I-Sce I*. a) Maps of the 7.5 kb *tk -PhleoLacZ* retrovirus (G-MtkPL) and of the 6.0 kb *PhleoLacZ* retrovirus (G-MPL), SA is splice acceptor site. G-MtkPL sequences (from G-MtkPL virus) contains *PhleoLacZ* fusion gene for positive selection of infected cells (in phleomycin-containing medium) and *tk* gene for negative selection (in gancyclovir-containing medium). G-MPL sequences (from G-MPL virus) contains only

002270" 25926460

*PhleoLacZ* sequences. b) Maps of proviral structures following retroviral integration of G-MtkPL and G-MPL. I-Sce I *PhleoLacZ* LTR duplicates, placing I-Sce I *PhleoLacZ* sequences in the 5' LTR. The virus vector (which functions as a promoter trap) is transcribed (arrow) by a flanking cellular promoter, P. c) I-Sce I creates two double strand breaks (DSBs) in host DNA liberating the central segment and leaving broken chromosome ends that can pair with the donor plasmid, pVRneo (d). e) Expected recombinant locus following HR.

**Figure 21. A.** Scheme of pG-MPL. SD and SA are splice donor and splice acceptor sites. The structure of the unspliced 5.8 kb (genomic) and spliced 4;2 kb transcripts is shown below. Heavy bar is <sup>32</sup>P radiolabelled *LacZ* probe (P). B. RNA Northern blot analysis of a pG MLP transformed ψ-2 producer clone using polyadenylated RNA. Note that the genomic and the spliced mRNA are produced at the same high level.

**Figure 22. A.** Introduction of duplicated I-Sce I recognition sites into the genome of mammalian cells by retrovirus integration. Scheme of G-MPL and G-MtkPL proviruses which illustrates positions of the two LTRs and pertinent restriction sites. The size of *Bcl* I fragments and of I-Sce I fragments are indicated. Heavy bar is <sup>32</sup>P radiolabelled *LacZ* probe (P). B. Southern blot analysis of cellular DNA from NIH3T3 fibroblasts cells infected by G-MtkPL and PCC7-S multipotent cells infected by G-MPL. *Bcl* I

002270 45925460

digests demonstrating LTR mediated *PhleoLacZ* duplication; I-Sce I digests demonstrating faithful duplication of I-Sce I sites.

**Figure 23.** Verification of recombination by Southern. A.: Expected fragment sizes in kilobase pairs (kb) of provirus at the recombinant locus. 1) the parental proviral locus. Heavy bar (P) is  $^{32}\text{P}$  radioactively labelled probe used for hybridization. 2) a recombinant derived after cleavage at the two I-Sce I sites followed by gap repair using pVR neo (double-site homologous recombination, DsHR). 3) a recombination event initiated by the cleavage at the I-Sce I sites in the left LTR (single-site homologous recombination, SsHR). B.: Southern analysis of DNA from NIH3T3/G-MtkPL clones 1 and 2, PCC7-S/G-MPL clones 3 and 4 and transformants derived from cotransfection with pCMV(I-Sce I+) and pVRneo (1a, 1b, 2a, 3a, 3b and 4a). *Kpn* I digestion of the parental DNA generates a 4.2 kb fragment containing *LacZ* fragment. Recombinants 1a and 3a are examples of DsHR Recombinants 1b, 2a, 3b and 4a are examples of SsHR.

**Figure 24.** Verification of recombination by Northern blot analyses. A.: Expected structure and sizes (in kb) of RNA from PCC7-S/G-MPL clone 3 cells before (top) and after (bottom) I-Sce I induced HR with pVRneo.1 Heavy bars P1 and P2 are  $^{32}\text{P}$  radioactively labelled probes. B.: Northern blot analysis of the PCC7-S/G-MPL clone 3 recombinant (total RNA). Lane 3 is parental cells, lane 3a recombinant cells. Two first lanes were probed with *LacZ* P1, two last lanes are

09453657-03200

probed with neo P2. parental PCC7-S/G-MPL clone 3 cells express a 7.0 kb *LacZ* RNA as expected of trapping of a cellular promoter leading to expression of a cellular-viral fusion RNA. The recombinant clone does not express this *LacZ* RNA but expresses a neo RNA of 5.0 kb, corresponding to the size expected for an accurate replacement of *PhleoLacZ* by neo gene.

**Figure 25.** Types of recombination events induced by I-Sce I DSBs, a) Schematic drawing of the structure of the recombination substrate. The G-MtkPL has provirus two LTRs, each containing an I-Sce I recognition site and a *PhleoLacZ* gene. The LTRs are separated by viral sequences containing the *tk* gene. The phenotype of G-MtkPL containing cells is  $Phleo^R$ ,  $GI^S$ ,  $\beta$ -Gal $\pm$  b) Possible modes of intra-chromosomal recombination. 1) The I-Sce I endonuclease cuts the I-Sce I site in the 5'LTR. The 5' part of U3 of the 5'LTR can pair and recombine with it homologous sequence in the 3'LTR (by SSA). 2) The I-Sce I endonuclease cuts the I-Sce I site in the 3'LTR. The 3' part of U3 of the 3'LTR can pair and recombine with its homologous sequence in the 5'LTR (by SSA). 3) The I-Sce I endonuclease cuts I-Sce I sites in the two LTRs. The two free ends can relegate (by an end-joining mechanism). The resulting recombination product in each of the three models is a solitary LTR (see right side). No modification would occur in the cellular sequences flanking the integration site. c) The I-Sce I endonuclease cuts the I-Sce I sites in the two LTRs. The two free ends can be repaired (by a gap repair mechanism) using the homologous

004937-012700

chromosome. On the right, the resulting recombination product is the deletion of the proviral integration locus.

**Figure 26.** Southern blot analysis of DNA from NIH3T3/G-MtkPL 1 and 2, and *PhleoLacZ*<sup>-</sup> recombinants derived from transfections with pCMV(I-Sce I+) selected in Gancyclovir containing medium. a) Expected fragment sizes in kilobase pair (kbp) of parental provirus after digestion with *Pst* I endonuclease. *Pst* I digestion of the parental DNA NIH3T3/G-MtkPL 1 generates two fragments of 10 kbp and of the parental NIH3T3/G-MtkPL 2 two fragments of 7 kbp and 9 kbp. b) Southern blot analysis of DNA digested by *Pst* I from NIH3T3/G-MtkPL 1, and recombinants derived from transfection with pCMV(I-Sce I+) (1.1 to 1.5). c) Southern blot analysis of DNA digested by *Pst* I from NIH3T3/G-MtkPL 2, and recombinants derived from transfection with pCMV(I-Sce I+) (2.1 to 2.6). Heavy bar is <sup>32</sup>P radiolabelled *LacZ* probe (P).

**Figure 27.** Southern blot analysis of DNA from NIH3T3/G-MtkPL 1 and 2, and *PhleoLacZ*<sup>+</sup> recombinants derived from transfections with pCMV(I-Sce I+) and pCMV(I-Sce I-) and selection in Phleomycin and Gancyclovir containing medium. a) Expected fragment sizes in kbp of parental provirus after digestion with *Pst* I or *Bcl* I endonuclease. *Pst* I digestion of the parental DNA NIH3T3/G-MtkPL 1 generates two fragments of 10 kbp. *Bcl* I digestion of the parental DNA NIH3T3/G-MtkPL 2 generates three fragments of 9.2 kbp, 7.2 kbp and 6.0 kbp. a2) Expected fragment sizes in kbp of recombinants after digestion with *Pst* I or *Bcl* I endonuclease. *Pst* I

digestion of DNA of the recombinant derived from NIH3T3/G-MtkPL 1 generates one fragment of 13.6 kbp. *Bcl* I digestion of the DNA of the recombinants derived from NIH3T3/G-MtkPL 2 generates two fragments of 9.2 kbp and 6.0 kbp. b) Southern blot analysis of DNA from NIH3T3/G-MtkPL 1, and recombinants derived from transfection with pCMV(I-Sce I-) and pCMV(I-Sce I+) (1c, 1d). c) Southern analysis of DNA from NIH3T3/G-MtkPL 2, and transformants derived from transfection with pCMV(I-Sce I-) (2a, 2b) and pCMV(I-Sce I+) (2c to 2h).

Heavy bar is  $^{32}\text{P}$  radiolabelled *LacZ* probe (P).

**Figure 28.** Figure 28 is a diagram illustrating the loss of heterozygosity by the insertion or presence of an I-Sce I site, expression of the enzyme I-Sce I, cleavage at the site, and repair of the double strand break at the site with the corresponding chromatid.

**Figure 29.** Figure 29 is a diagram illustrating conditional activation of a gene. An I-Sce I site is integrated between tandem repeats, and the enzyme I-Sce I is expressed. The enzyme cleaves the double stranded DNA at the I-Sce I site. The double strand break is repaired by single strand annealing, yielding an active gene.

**Figure 30.** Figure 30 is a diagram illustrating one step rearrangement of a gene by integration of an I-Sce I site or by use of an I-Sce I site present in the gene. A plasmid having either one I-Sce I site within an inactive gene, or two I-Sce I sites at either end of an active gene without a promoter, is introduced into the cell. The cell

contains an inactive form of the corresponding gene. The enzyme I-Sce I cuts the plasmid at the I-Sce I sites, and recombination between the chromosome and the plasmid yields an active gene replacing the inactive gene.

**Figure 31.** Figure 31 is a diagram illustrating the duplication of a locus. An I-Sce I site and a distal part of the locus are inserted into the gene by classical gene replacement. The I-Sce I site is cleaved by I-Sce I enzyme, and the break is repaired by homologous sequences. This results in duplication of the entire locus.

**Figure 32.** Figure 30 is a diagram illustrating the deletion of a locus. Two I-Sce I sites are added to flank the locus to be deleted. The I-Sce I enzyme is expressed, and the sites are cleaved. The two remaining ends recombine, deleting the locus between the two I-Sce I sites.

**Figure 33.** Figure 33 is a diagram of plasmid pG-MtkΔPAPL showing the restriction sites. The plasmid is constructed by deletion of the polyadenylation region of the tk gene from the pGMtkPL plasmid.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The genuine mitochondrial gene (ref. 8) cannot be expressed in *E. coli*, yeast or other organisms due to the peculiarities of the mitochondrial genetic code. A "universal code equivalent" has been constructed by *in vitro* site-directed mutagenesis. Its sequence is given in Fig. 1. Note that all non-universal codons (except two CTN) have been replaced together with some codons extremely rare in *E. coli*.



The universal code equivalent has been successfully expressed in *E. coli* and determines the synthesis of an active enzyme. However, expression levels remained low due to the large number of codons that are extremely rare in *E. coli*. Expression of the "universal code equivalent" has been detected in yeast.

To optimize gene expression in heterologous systems, a synthetic gene has been designed to encode a protein with the genuine amino acid sequence of I-SceI using, for each codon, that most frequently used in *E. coli*. The sequence of the synthetic gene is given in Fig. 2. The synthetic gene was constructed *in vitro* from eight synthetic oligonucleotides with partial overlaps. Oligonucleotides were designed to allow mutual priming for second strand synthesis by Klenow polymerase when annealed by pairs. The elongated pairs were then ligated into plasmids. Appropriately placed restriction sites within the designed sequence allowed final assembly of the synthetic gene by *in vitro* ligation. The synthetic gene has been successfully expressed in both *E. coli* and yeast.

#### 1. I-SceI Gene Sequence

This invention relates to an isolated DNA sequence encoding the enzyme I-SceI. The enzyme I-SceI is an endonuclease. The properties of the enzyme (ref. 14) are as follows:

I-SceI is a double-stranded endonuclease that cleaves DNA within its recognition site. I-SceI generates a 4bp staggered cut with 3'OH overhangs.

Substrate: Acts only on double-stranded DNA. Substrate DNA can be relaxed or negatively supercoiled.

Cations: Enzymatic activity requires  $Mg^{++}$  (8 mM is optimum).  $Mn^{++}$  can replace  $Mg^{++}$ , but this reduces the stringency of recognition.

Optimum conditions for activity: high pH (9 to 10), temperature 20-40°C, no monovalent cations.

Enzyme stability: I-SceI is unstable at room temperature. The enzyme-substrate complex is more stable than the enzyme alone (presence of recognition sites stabilizes the enzyme.)

The enzyme I-SceI has a known recognition site. (ref. 14.) The recognition site of I-SceI is a non-symmetrical sequence that extends over 18 bp as determined by systematic mutational analysis. The sequence reads: (arrows indicate cuts)

5' TAGGGATAACAGGGTAAT 3'  
3' ATCCCTATTGTCCCATTA 5'

002270 2592460

The recognition site corresponds, in part, to the upstream exon and, in part, to the downstream exon of the intron plus form of the gene.

The recognition site is partially degenerate: single base substitutions within the 18 bp long sequence result in either complete insensitivity or reduced sensitivity to the enzyme, depending upon position and nature of the substitution.

The stringency of recognition has been measured on:

-1- mutants of the site.

-2- the total yeast genome (*Saccharomyces cerevisiae*, genome complexity is  $1.4 \times 10^7$  bp). Data are unpublished.

Results are:

-1- Mutants of the site: As shown in Fig. 3, there is a general shifting of stringency, i.e., mutants severely affected in  $Mg^{++}$  become partially affected in  $Mn^{++}$ , mutants partially affected in  $Mg^{++}$  become unaffected in  $Mn^{++}$ .

-2- Yeast: In magnesium conditions, no cleavage is observed in normal yeast. In the same condition, DNA from transgenic yeasts is cleaved to completion at the artificially inserted I-SceI site and no other cleavage site can be detected. If magnesium is replaced by manganese, five additional cleavage sites are revealed in the entire yeast genome, none of which is cleaved to completion. Therefore, in manganese the enzyme reveals

0022707693460

an average of 1 site for ca. 3 millions based pairs (5/  
 $1.4 \times 10^7$  bp).

Definition of the recognition site: important bases are indicated in Fig. 3. They correspond to bases for which severely affected mutants exist. Notice however that:

-1- All possible mutations at each position have not been determined; therefore a base that does not correspond to a severely affected mutant may still be important if another mutant was examined at this very same position.

-2- There is no clear-cut limit between a very important base (all mutants are severely affected) and a moderately important base (some of the mutants are severely affected). There is a continuum between excellent substrates and poor substrates for the enzyme.

The expected frequency of natural I-SceI sites in a random DNA sequence is, therefore, equal to  $(0.25)^{-18}$  or  $(1.5 \times 10^{-11})$ . In other words, one should expect one natural site for the equivalent of ca. 20 human genomes, but the frequency of degenerate sites is more difficult to predict.

I-SceI belongs to a "degenerate" subfamily of the two-dodecapeptide family. Conserved amino acids of the dodecapeptide motifs are required for activity. In particular, the aspartic residues at positions 9 of the two dodecapeptides cannot be replaced, even with

09452697 012700

glutamic residues. It is likely that the dodecapeptides form the catalytic site or part of it.

Consistent with the recognition site being non-symmetrical, it is likely that the endonucleolytic activity of I-SceI requires two successive recognition steps: binding of the enzyme to the downstream half of the site (corresponding to the downstream exon) followed by binding of the enzyme to the upstream half of the site (corresponding to the upstream exon). The first binding is strong, the second is weaker, but the two are necessary for cleavage of DNA. *In vitro*, the enzyme can bind the downstream exon alone as well as the intron-exon junction sequence, but no cleavage results.

The evolutionarily conserved dodecapeptide motifs of intron-encoded I-SceI are essential for endonuclease activity. It has been proposed that the role of these motifs is to properly position the acidic amino acids with respect to the DNA sequence recognition domains of the enzyme for the catalysis of phosphodiester bond hydrolysis (ref. P3).

The nucleotide sequence of the invention, which encodes the natural I-SceI enzyme is shown in Fig. 2. The nucleotide sequence of the gene of the invention was derived by dideoxynucleotide sequencing. The base sequences of the nucleotides are written in the 5'----->3' direction. Each of the letters shown is a conventional designation for the following nucleotides:

A	Adenine
G	Guanine

00492697 "042700"

T      Thymine  
C      Cytosine.

It is preferred that the DNA sequence encoding the enzyme I-SceI be in a purified form. For instance, the sequence can be free of human blood-derived proteins, human serum proteins, viral proteins, nucleotide sequences encoding these proteins, human tissue, human tissue components, or combinations of these substances. In addition, it is preferred that the DNA sequence of the invention is free of extraneous proteins and lipids, and adventitious microorganisms, such as bacteria and viruses. The essentially purified and isolated DNA sequence encoding I-SceI is especially useful for preparing expression vectors.

Plasmid pSCM525 is a pUC12 derivative, containing an artificial sequence encoding the DNA sequence of the invention. The nucleotide sequence and deduced amino acid sequence of a region of plasmid pSCM525 is shown in Fig. 4. The nucleotide sequence of the invention encoding I-SceI is enclosed in the box. The artificial gene is a *Bam*HI - *Sal*I piece of DNA sequence of 723 base pairs, chemically synthesized and assembled. It is placed under *tac* promoter control. The DNA sequence of the artificial gene differs from the natural coding sequence or its universal code equivalent described in Cell (1986), Vol. 44, pages 521-533. However, the translation product of the artificial gene is identical in sequence to the genuine omega-endonuclease except for the addition of a Met-His at the N-terminus. It

will be understood that this modified endonuclease is within the scope of this invention.

Plasmid pSCM525 can be used to transform any suitable *E. coli* strain and transformed cells become ampicillin-resistant. Synthesis of the omega-endonuclease is obtained by addition of I.P.T.G. or an equivalent inducer of the lactose operon system.

A plasmid identified as pSCM525 containing the enzyme I-SceI was deposited in *E. coli* strain TG1 with the Collection Nationale de Cultures de Microorganismes (C.N.C.M.) of Institut Pasteur in Paris, France on November 22, 1990, under culture collection deposit Accession No. I-1014. The nucleotide sequence of the invention is thus available from this deposit.

The gene of the invention can also be prepared by the formation of 3'----->5' phosphate linkages between nucleoside units using conventional chemical synthesis techniques. For example, the well-known phosphodiester, phosphotriester, and phosphite triester techniques, as well as known modifications of these approaches, can be employed. Deoxyribonucleotides can be prepared with automatic synthesis machines, such as those based on the phosphoramidite approach. Oligo- and polyribonucleotides can also be obtained with the aid of RNA ligase using conventional techniques.

This invention of course includes variants of the DNA sequence of the invention exhibiting substantially the same properties as the sequence of the invention. By this it is

00492697-01300

meant that DNA sequences need not be identical to the sequence disclosed herein. Variations can be attributable to single or multiple base substitutions, deletions, or insertions or local mutations involving one or more nucleotides not substantially detracting from the properties of the DNA sequence as encoding an enzyme having the cleavage properties of the enzyme I-SceI.

Fig. 5 depicts some of the variations that can be made around the I-SceI amino acid sequence. It has been demonstrated that the following positions can be changed without affecting enzyme activity:

positions -1 and -2 are not natural. The two amino acids are added due to cloning strategies.  
positions 1 to 10: can be deleted.  
position 36: G is tolerated.  
position 40: M or V are tolerated.  
position 41: S or N are tolerated.  
position 43: A is tolerated.  
position 46: V or N are tolerated.  
position 91: A is tolerated.  
positions 123 and 156: L is tolerated.  
position 223: A and S are tolerated.

It will be understood that enzymes containing these modifications are within the scope of this invention.

Changes to the amino acid sequence in Fig. 5 that have been demonstrated to affect enzyme activity are as follows:

position 19: L to S  
position 38: I to S or N  
position 39: G to D or R  
position 40: L to Q  
position 42: L to R  
position 44: D to E, G or H  
position 45: A to E or D  
position 46: Y to D  
position 47: I to R or N  
position 80: L to S  
position 144: D to E



position 145: D to E  
position 146: G to E  
position 147: G to S

It will also be understood that the present invention is intended to encompass fragments of the DNA sequence of the invention in purified form, where the fragments are capable of encoding enzymatically active I-SceI.

The DNA sequence of the invention coding for the enzyme I-SceI can be amplified in the well known polymerase chain reaction (PCR), which is useful for amplifying all or specific regions of the gene. See e.g., S. Kwok et al., J. Virol., 61:1690-1694 (1987); U.S. Patent 4,683,202; and U.S. Patent 4,683,195. More particularly, DNA primer pairs of known sequence positioned 10-300 base pairs apart that are complementary to the plus and minus strands of the DNA to be amplified can be prepared by well known techniques for the synthesis of oligonucleotides. One end of each primer can be extended and modified to create restriction endonuclease sites when the primer is annealed to the DNA. The PCR reaction mixture can contain the DNA, the DNA primer pairs, four deoxyribonucleoside triphosphates,  $MgCl_2$ , DNA polymerase, and conventional buffers. The DNA can be amplified for a number of cycles. It is generally possible to increase the sensitivity of detection by using a multiplicity of cycles, each cycle consisting of a short period of denaturation of the DNA at an elevated temperature, cooling of the reaction mixture,

0049369 04270 25925450

The enzyme I-*SceI* is one of a number of endonucleases with similar properties. Following is a listing of related enzymes and their sources.

Enzyme	Encoded by	Ref
I-SceI	Sc LSU-1 intron	this work
I-SceII	Sc cox1-4 intron	Sargueil et al., NAR (1990) 18, 5659-5665
I-SceIII	Sc cox1-3 intron	Sargueil et al., MGG (1991) 225, 340-341
I-SceIV	Sc cox1-5a intron	Seraphin et al. (1992) in press
I-CeuI	Ce LSU-5 intron	Marshall, Lemieux Gene (1991) 104, 241-245
I-CreI	Cr LSU-1 intron	Rochaix (unpublished)
I-PpoI	Pp LSU-3 intron	Muscarella et al., MCB (1990) 10, 3386-3396
I-TevI	T4 td-1 intron	Chu et al., PNAS (1990) 87, 3574-3578 and Bell- Pedersen et al. NAR (1990) 18, 3763-3770.
I-TevII	T4 sunY intron	Bell-Pedersen et al. NAR (1990) 18, 3763-3770.
I-TevIII	RB3 nrdB-1 intron	Eddy, Gold, Genes Dev. (1991) 5, 1032-1041
HO	HO yeast gene	Nickoloff et al., MCB (1990) 10, 1174-1179
Endo SceI	RF3 yeast mito. gene	Kawasaki et al., JBC (1991) 266, 5342-5347

Putative new enzymes (genetic evidence but no activity as yet) are I-CsmI from cytochrome b intron 1 of *Chlamydomonas smithii* mitochondria (ref. 15), I-PanI from cytochrome b intron 3 of *Podospira anserina* mitochondria (Jill Salvo), and

probably enzymes encoded by introns Nc nd1'1 and Nc cob'1  
from *Neurospora crassa*.

The I-endonucleases can be classified as follows:

Class I: Two dodecapeptide motifs, 4 bp staggered cut with 3' OH overhangs, cut internal to recognition site

<u>Subclass "I-SceI"</u>	<u>Other subclasses</u>
<p>1. <i>ScdI</i></p> <p>2. <i>ScdII</i></p> <p>3. <i>ScdIII</i></p> <p>4. <i>ScdIV</i></p> <p>5. <i>ScdV</i></p> <p>6. <i>ScdVI</i></p> <p>7. <i>ScdVII</i></p> <p>8. <i>ScdVIII</i></p> <p>9. <i>ScdIX</i></p> <p>10. <i>ScdX</i></p> <p>11. <i>ScdXI</i></p> <p>12. <i>ScdXII</i></p> <p>13. <i>ScdXIII</i></p> <p>14. <i>ScdXIV</i></p> <p>15. <i>ScdXV</i></p> <p>16. <i>ScdXVI</i></p> <p>17. <i>ScdXVII</i></p> <p>18. <i>ScdXVIII</i></p> <p>19. <i>ScdXIX</i></p> <p>20. <i>ScdXX</i></p> <p>21. <i>ScdXXI</i></p> <p>22. <i>ScdXXII</i></p> <p>23. <i>ScdXXIII</i></p> <p>24. <i>ScdXXIV</i></p> <p>25. <i>ScdXXV</i></p> <p>26. <i>ScdXXVI</i></p> <p>27. <i>ScdXXVII</i></p> <p>28. <i>ScdXXVIII</i></p> <p>29. <i>ScdXXIX</i></p> <p>30. <i>ScdXXX</i></p> <p>31. <i>ScdXXXI</i></p> <p>32. <i>ScdXXXII</i></p> <p>33. <i>ScdXXXIII</i></p> <p>34. <i>ScdXXXIV</i></p> <p>35. <i>ScdXXXV</i></p> <p>36. <i>ScdXXXVI</i></p> <p>37. <i>ScdXXXVII</i></p> <p>38. <i>ScdXXXVIII</i></p> <p>39. <i>ScdXXXIX</i></p> <p>40. <i>ScdXXXX</i></p> <p>41. <i>ScdXXXXI</i></p> <p>42. <i>ScdXXXXII</i></p> <p>43. <i>ScdXXXXIII</i></p> <p>44. <i>ScdXXXXIV</i></p> <p>45. <i>ScdXXXXV</i></p> <p>46. <i>ScdXXXXVI</i></p> <p>47. <i>ScdXXXXVII</i></p> <p>48. <i>ScdXXXXVIII</i></p> <p>49. <i>ScdXXXXIX</i></p> <p>50. <i>ScdXXXXX</i></p> <p>51. <i>ScdXXXXXI</i></p> <p>52. <i>ScdXXXXXII</i></p> <p>53. <i>ScdXXXXXIII</i></p> <p>54. <i>ScdXXXXXIV</i></p> <p>55. <i>ScdXXXXXV</i></p> <p>56. <i>ScdXXXXXVI</i></p> <p>57. <i>ScdXXXXXVII</i></p> <p>58. <i>ScdXXXXXVIII</i></p> <p>59. <i>ScdXXXXXIX</i></p> <p>60. <i>ScdXXXXXX</i></p> <p>61. <i>ScdXXXXXXI</i></p> <p>62. <i>ScdXXXXXXII</i></p> <p>63. <i>ScdXXXXXXIII</i></p> <p>64. <i>ScdXXXXXXIV</i></p> <p>65. <i>ScdXXXXXXV</i></p> <p>66. <i>ScdXXXXXXVI</i></p> <p>67. <i>ScdXXXXXXVII</i></p> <p>68. <i>ScdXXXXXXVIII</i></p> <p>69. <i>ScdXXXXXXIX</i></p> <p>70. <i>ScdXXXXXXX</i></p> <p>71. <i>ScdXXXXXXXI</i></p> <p>72. <i>ScdXXXXXXXII</i></p> <p>73. <i>ScdXXXXXXXIII</i></p> <p>74. <i>ScdXXXXXXXIV</i></p> <p>75. <i>ScdXXXXXXXV</i></p> <p>76. <i>ScdXXXXXXXVI</i></p> <p>77. <i>ScdXXXXXXXVII</i></p> <p>78. <i>ScdXXXXXXXVIII</i></p> <p>79. <i>ScdXXXXXXXIX</i></p> <p>80. <i>ScdXXXXXXXI</i></p> <p>81. <i>ScdXXXXXXXII</i></p> <p>82. <i>ScdXXXXXXXIII</i></p> <p>83. <i>ScdXXXXXXXIV</i></p> <p>84. <i>ScdXXXXXXXV</i></p> <p>85. <i>ScdXXXXXXXVI</i></p> <p>86. <i>ScdXXXXXXXVII</i></p> <p>87. <i>ScdXXXXXXXVIII</i></p> <p>88. <i>ScdXXXXXXXIX</i></p> <p>89. <i>ScdXXXXXXXI</i></p> <p>90. <i>ScdXXXXXXXII</i></p> <p>91. <i>ScdXXXXXXXIII</i></p> <p>92. <i>ScdXXXXXXXIV</i></p> <p>93. <i>ScdXXXXXXXV</i></p> <p>94. <i>ScdXXXXXXXVI</i></p> <p>95. <i>ScdXXXXXXXVII</i></p> <p>96. <i>ScdXXXXXXXVIII</i></p> <p>97. <i>ScdXXXXXXXIX</i></p> <p>98. <i>ScdXXXXXXXI</i></p> <p>99. <i>ScdXXXXXXXII</i></p> <p>100. <i>ScdXXXXXXXIII</i></p> <p>101. <i>ScdXXXXXXXIV</i></p> <p>102. <i>ScdXXXXXXXV</i></p> <p>103. <i>ScdXXXXXXXVI</i></p> <p>104. <i>ScdXXXXXXXVII</i></p> <p>105. <i>ScdXXXXXXXVIII</i></p> <p>106. <i>ScdXXXXXXXIX</i></p> <p>107. <i>ScdXXXXXXXI</i></p> <p>108. <i>ScdXXXXXXXII</i></p> <p>109. <i>ScdXXXXXXXIII</i></p> <p>110. <i>ScdXXXXXXXIV</i></p> <p>111. <i>ScdXXXXXXXV</i></p> <p>112. <i>ScdXXXXXXXVI</i></p> <p>113. <i>ScdXXXXXXXVII</i></p> <p>114. <i>ScdXXXXXXXVIII</i></p> <p>115. <i>ScdXXXXXXXIX</i></p> <p>116. <i>ScdXXXXXXXI</i></p> <p>117. <i>ScdXXXXXXXII</i></p> <p>118. <i>ScdXXXXXXXIII</i></p> <p>119. <i>ScdXXXXXXXIV</i></p> <p>120. <i>ScdXXXXXXXV</i></p> <p>121. <i>ScdXXXXXXXVI</i></p> <p>122. <i>ScdXXXXXXXVII</i></p> <p>123. <i>ScdXXXXXXXVIII</i></p> <p>124. <i>ScdXXXXXXXIX</i></p> <p>125. <i>ScdXXXXXXXI</i></p> <p>126. <i>ScdXXXXXXXII</i></p> <p>127. <i>ScdXXXXXXXIII</i></p> <p>128. <i>ScdXXXXXXXIV</i></p> <p>129. <i>ScdXXXXXXXV</i></p> <p>130. <i>ScdXXXXXXXVI</i></p> <p>131. <i>ScdXXXXXXXVII</i></p> <p>132. <i>ScdXXXXXXXVIII</i></p> <p>133. <i>ScdXXXXXXXIX</i></p> <p>134. <i>ScdXXXXXXXI</i></p> <p>135. <i>ScdXXXXXXXII</i></p> <p>136. <i>ScdXXXXXXXIII</i></p> <p>137. <i>ScdXXXXXXXIV</i></p> <p>138. <i>ScdXXXXXXXV</i></p> <p>139. <i>ScdXXXXXXXVI</i></p> <p>140. <i>ScdXXXXXXXVII</i></p> <p>141. <i>ScdXXXXXXXVIII</i></p> <p>142. <i>ScdXXXXXXXIX</i></p> <p>143. <i>ScdXXXXXXXI</i></p> <p>144. <i>ScdXXXXXXXII</i></p> <p>145. <i>ScdXXXXXXXIII</i></p> <p>146. <i>ScdXXXXXXXIV</i></p> <p>147. <i>ScdXXXXXXXV</i></p> <p>148. <i>ScdXXXXXXXVI</i></p> <p>149. <i>ScdXXXXXXXVII</i></p> <p>150. <i>ScdXXXXXXXVIII</i></p> <p>151. <i>ScdXXXXXXXIX</i></p> <p>152. <i>ScdXXXXXXXI</i></p> <p>153. <i>ScdXXXXXXXII</i></p> <p>154. <i>ScdXXXXXXXIII</i></p> <p>155. <i>ScdXXXXXXXIV</i></p> <p>156. <i>ScdXXXXXXXV</i></p> <p>157. <i>ScdXXXXXXXVI</i></p> <p>158. <i>ScdXXXXXXXVII</i></p> <p>159. <i>ScdXXXXXXXVIII</i></p> <p>160. <i>ScdXXXXXXXIX</i></p> <p>161. <i>ScdXXXXXXXI</i></p> <p>162. <i>ScdXXXXXXXII</i></p> <p>163. <i>ScdXXXXXXXIII</i></p> <p>164. <i>ScdXXXXXXXIV</i></p> <p>165. <i>ScdXXXXXXXV</i></p> <p>166. <i>ScdXXXXXXXVI</i></p> <p>167. <i>ScdXXXXXXXVII</i></p> <p>168. <i>ScdXXXXXXXVIII</i></p> <p>169. <i>ScdXXXXXXXIX</i></p> <p>170. <i>ScdXXXXXXXI</i></p> <p>171. <i>ScdXXXXXXXII</i></p> <p>172. <i>ScdXXXXXXXIII</i></p> <p>173. <i>ScdXXXXXXXIV</i></p> <p>174. <i>ScdXXXXXXXV</i></p> <p>175. <i>ScdXXXXXXXVI</i></p> <p>176. <i>ScdXXXXXXXVII</i></p> <p>177. <i>ScdXXXXXXXVIII</i></p> <p>178. <i>ScdXXXXXXXIX</i></p> <p>179. <i>ScdXXXXXXXI</i></p> <p>180. <i>ScdXXXXXXXII</i></p> <p>181. <i>ScdXXXXXXXIII</i></p> <p>182. <i>ScdXXXXXXXIV</i></p> <p>183. <i>ScdXXXXXXXV</i></p> <p>184. <i>ScdXXXXXXXVI</i></p> <p>185. <i>ScdXXXXXXXVII</i></p> <p>186. <i>ScdXXXXXXXVIII</i></p> <p>187. <i>ScdXXXXXXXIX</i></p> <p>188. <i>ScdXXXXXXXI</i></p> <p>189. <i>ScdXXXXXXXII</i></p> <p>190. <i>ScdXXXXXXXIII</i></p> <p>191. <i>ScdXXXXXXXIV</i></p> <p>192. <i>ScdXXXXXXXV</i></p> <p>193. <i>ScdXXXXXXXVI</i></p> <p>194. <i>ScdXXXXXXXVII</i></p> <p>195. <i>ScdXXXXXXXVIII</i></p> <p>196. <i>ScdXXXXXXXIX</i></p> <p>197. <i>ScdXXXXXXXI</i></p> <p>198. <i>ScdXXXXXXXII</i></p> <p>199. <i>ScdXXXXXXXIII</i></p> <p>200. <i>ScdXXXXXXXIV</i></p> <p>201. <i>ScdXXXXXXXV</i></p> <p>202. <i>ScdXXXXXXXVI</i></p> <p>203. <i>ScdXXXXXXXVII</i></p> <p>204. <i>ScdXXXXXXXVIII</i></p> <p>205. <i>ScdXXXXXXXIX</i></p> <p>206. <i>ScdXXXXXXXI</i></p> <p>207. <i>ScdXXXXXXXII</i></p> <p>208. <i>ScdXXXXXXXIII</i></p> <p>209. <i>ScdXXXXXXXIV</i></p> <p>210. <i>ScdXXXXXXXV</i></p> <p>211. <i>ScdXXXXXXX</i></p>	

I-SceI	I-SceII
I-SceIV	I-SceIII
I-CsmI	I-CeuI (only one dodecapeptide motif)
I-PanI	I-CreI (only one dodecapeptide motif)
	HO
	TFP1-408 (HO homolog)
	Endo SceI

Class II: GIY-(N<sub>10-11</sub>) YIG motif, 2 bp staggered cut with 3' OH overhangs, cut external to recognition site:

I-TevI

Class III: no typical structural motifs, 4 bp staggered cut with 3' OH overhangs, cut internal to recognition site:

I - PpOI

Class IV: no typical structural motifs, 2 bp staggered cut with 3' OH overhangs, cut external to recognition site:

I - TevII

Class V: no typical structural motifs, 2 bp staggered cut with 5' OH overhangs:

I-TevIII.

2. Nucleotide Probes Containing the I-SceI  
Gene of The Invention

The DNA sequence of the invention coding for the enzyme I-SceI can also be used as a probe for the detection of a nucleotide sequence in a biological material, such as tissue or body fluids. The probe can be labeled with an atom or inorganic radical, most commonly using a radionuclide, but also perhaps with a heavy metal. Radioactive labels include  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$ , or the like. Any radioactive label can be employed, which provides for an adequate signal and has sufficient half-life. Other labels include ligands that can serve as a specific binding member to a labeled antibody, fluorescers, chemiluminescers, enzymes, antibodies which can serve as a specific binding pair member for a labeled ligand, and the like. The choice of the label will be governed by the effect of the label on the rate of hybridization and binding of the probe to the DNA or RNA. It will be necessary that the label provide sufficient sensitivity to detect the amount of DNA or RNA available for hybridization.

When the nucleotide sequence of the invention is used as a probe for hybridizing to a gene, the nucleotide sequence is preferably affixed to a water insoluble solid, porous support, such as nitrocellulose paper. Hybridization can be carried out using labeled polynucleotides of the invention and conventional hybridization reagents. The particular hybridization technique is not essential to the invention.

The amount of labeled probe present in the hybridization solution will vary widely, depending upon the nature of the

00493697 012700

label, the amount of the labeled probe which can reasonably bind to the support, and the stringency of the hybridization. Generally, substantial excesses of the probe over stoichiometric will be employed to enhance the rate of binding of the probe to the fixed DNA.

Various degrees of stringency of hybridization can be employed. The more severe the conditions, the greater the complementarity that is required for hybridization between the probe and the polynucleotide for duplex formation. Severity can be controlled by temperature, probe concentration, probe length, ionic strength, time, and the like. Conveniently, the stringency of hybridization is varied by changing the polarity of the reactant solution. Temperatures to be employed can be empirically determined or determined from well known formulas developed for this purpose.

3. Nucleotide Sequences Containing the  
Nucleotide Sequence Encoding I-SceI

This invention also relates to the DNA sequence of the invention encoding the enzyme I-SceI, wherein the nucleotide sequence is linked to other nucleic acids. The nucleic acid can be obtained from any source, for example, from plasmids, from cloned DNA or RNA, or from natural DNA or RNA from any source, including prokaryotic and eukaryotic organisms. DNA or RNA can be extracted from a biological material, such as biological fluids or tissue, by a variety of techniques including those described by Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New

002210 1692460

'

1

## 4

V

C

major steps involved in gene cloning comprise procedures for separating DNA containing the gene of interest from prokaryotes or eukaryotes, cutting the resulting DNA fragment and the DNA from a cloning vehicle at specific sites, mixing the two DNA fragments together, and ligating the fragments to yield a recombinant DNA molecule. The recombinant molecule can then be transferred into a host cell, and the cells allowed to replicate to produce identical cells containing clones of the original DNA sequence.

The vehicle employed in this invention can be any double-stranded DNA molecule capable of transporting the nucleotide sequence of the invention into a host cell and capable of replicating within the cell. More particularly, the vehicle must contain at least one DNA sequence that can act as the origin of replication in the host cell. In addition, the vehicle must contain two or more sites for insertion of the DNA sequence encoding the gene of the invention. These sites will ordinarily correspond to restriction enzyme sites at which cohesive ends can be formed, and which are complementary to the cohesive ends on the promoter sequence to be ligated to the vehicle. In general, this invention can be carried out with plasmid, bacteriophage, or cosmid vehicles having these characteristics.

The nucleotide sequence of the invention can have cohesive ends compatible with any combination of sites in the vehicle. Alternatively, the sequence can have one or more blunt ends that can be ligated to corresponding blunt ends in the cloning sites of the vehicle. The nucleotide sequence to

00493957-01200

be ligated can be further processed, if desired, by successive exonuclease deletion, such as with the enzyme Bal 31. In the event that the nucleotide sequence of the invention does not contain a desired combination of cohesive ends, the sequence can be modified by adding a linker, an adaptor, or homopolymer tailing.

It is preferred that plasmids used for cloning nucleotide sequences of the invention carry one or more genes responsible for a useful characteristic, such as a selectable marker, displayed by the host cell. In a preferred strategy, plasmids having genes for resistance to two different drugs are chosen. For example, insertion of the DNA sequence into a gene for an antibiotic inactivates the gene and destroys drug resistance. The second drug resistance gene is not affected when cells are transformed with the recombinants, and colonies containing the gene of interest can be selected by resistance to the second drug and susceptibility to the first drug. Preferred antibiotic markers are genes imparting chloramphenicol, ampicillin, or tetracycline resistance to the host cell.

A variety of restriction enzymes can be used to cut the vehicle. The identity of the restriction enzyme will generally depend upon the identity of the ends on the DNA sequence to be ligated and the restriction sites in the vehicle. The restriction enzyme is matched to the restriction sites in the vehicle, which in turn is matched to the ends on the nucleic acid fragment being ligated.



The ligation reaction can be set up using well known techniques and conventional reagents. Ligation is carried out with a DNA ligase that catalyzes the formation of phosphodiester bonds between adjacent 5'-phosphate and the free 3'-hydroxy groups in DNA duplexes. The DNA ligase can be derived from a variety of microorganisms. The preferred DNA ligases are enzymes from *E. coli* and bacteriophage T4. T4 DNA ligase can ligate DNA fragments with blunt or sticky ends, such as those generated by restriction enzyme digestion. *E. coli* DNA ligase can be used to catalyze the formation of phosphodiester bonds between the termini of duplex DNA molecules containing cohesive ends.

Cloning can be carried out in prokaryotic or eukaryotic cells. The host for replicating the cloning vehicle will of course be one that is compatible with the vehicle and in which the vehicle can replicate. When a plasmid is employed, the plasmid can be derived from bacteria or some other organism or the plasmid can be synthetically prepared. The plasmid can replicate independently of the host cell chromosome or an integrative plasmid (episome) can be employed. The plasmid can make use of the DNA replicative enzymes of the host cell in order to replicate or the plasmid can carry genes that code for the enzymes required for plasmid replication. A number of different plasmids can be employed in practicing this invention.

The DNA sequence of the invention encoding the enzyme I-SceI can also be ligated to a vehicle to form an expression vector. The vehicle employed in this case is one in which it

is possible to express the gene operatively linked to a promoter in an appropriate host cell. It is preferable to employ a vehicle known for use in expressing genes in *E. coli*, yeast, or mammalian cells. These vehicles include, for example, the following *E. coli* expression vectors:

pSCM525, which is an *E. coli* expression vector derived from pUC12 by insertion of a tac promoter and the synthetic gene for I-SceI. Expression is induced by IPTG.

pGEXω6, which is an *E. coli* expression vector derived from pGEX in which the synthetic gene from pSCM525 for I-SceI is fused with the glutathione S transferase gene, producing a hybrid protein. The hybrid protein possesses the endonuclease activity.

pDIC73, which is an *E. coli* expression vector derived from pET-3C by insertion of the synthetic gene for I-SceI (NdeI - BamHI fragment of pSCM525) under T7 promoter control. This vector is used in strain BL21 (DE3) which expresses the T7 RNA polymerase under IPTG induction.

pSCM351, which is an *E. coli* expression vector derived from pUR291 in which the synthetic gene for I-SceI is fused with the Lac Z gene, producing a hybrid protein.

pSCM353, which is an *E. coli* expression vector derived from pEX1 in which the synthetic gene for I-SceI is fused with the Cro/Lac Z gene, producing a hybrid protein.

Examples of yeast expression vectors are:

pPEX7, which is a yeast expression vector derived from

004270 1596450

pPEX408, which is a yeast expression vector derived from pLG-SD5 by insertion of the synthetic gene under the control of the galactose promoter. Expression is induced by galactose.

Typical mammalian expression vectors are:

## 5. Cells Transformed with Vectors of the Invention

Cloning can be carried out in prokaryotic or eukaryotic cells. The host for replicating the cloning vehicle will of course be one that is compatible with the vehicle and in

which the vehicle can replicate. Cloning is preferably carried out in bacterial or yeast cells, although cells of fungal, animal, and plant origin can also be employed. The preferred host cells for conducting cloning work are bacterial cells, such as *E. coli*. The use of *E. coli* cells is particularly preferred because most cloning vehicles, such as bacterial plasmids and bacteriophages, replicate in these cells.

In a preferred embodiment of this invention, an expression vector containing the DNA sequence encoding the nucleotide sequence of the invention operatively linked to a promoter is inserted into a mammalian cell using conventional techniques.

#### Application of I-SceI for large scale mapping

##### 1. Occurrence of natural sites in various genomes

Using the purified I-SceI enzyme, the occurrence of natural or degenerate sites has been examined on the complete genomes of several species. No natural site was found in *Saccharomyces cerevisiae*, *Bacillus anthracis*, *Borrelia burgdorferi*, *Leptospira biflexa* and *L. interrogans*. One degenerate site was found on T7 phage DNA.

##### 2. Insertion of artificial sites

Given the absence of natural I-SceI sites, artificial sites can be introduced by transformation or transfection. Two cases need to be distinguished: site-directed integration by homologous recombination and random integration by

non-homologous recombination, transposon movement or retroviral infection. The first is easy in the case of yeast and a few bacterial species, more difficult for higher eucaryotes. The second is possible in all systems.

### 3. Insertion vectors

Two types can be distinguished:

-1- Site specific cassettes that introduce the *I-SceI* site together with a selectable marker.

For yeast: all are pAF100 derivatives (Thierry et al. (1990) YEAST 6:521-534) containing the following marker genes:

pAF101: URA3 (inserted in the *HindIII* site)

pAF103: Neo<sup>R</sup> (inserted in *BglII* site)

pAF104: HIS3 (inserted in *BglII* site)

pAF105: Kan<sup>R</sup> (inserted in *BglII* site)

pAF106: Kan<sup>R</sup> (inserted in *BglII* site)

pAF107: LYS2 (inserted between *HindIII* and *EcoR V*)

A restriction map of the plasmid pAF100 is shown in Fig. 9. The nucleotide sequence and restriction sites of regions of plasmid pAF100 are shown in Figs. 10A and 10B.

Many transgenic yeast strains with the *I-SceI* site at various and known places along chromosomes are available.

-2- Vectors derived from transposable elements or retroviruses.

For *E. coli* and other bacteria: mini Tn5 derivatives containing the I-SceI site and

pTsm  $\omega$  Str<sup>R</sup>

pTKm  $\omega$  Kan<sup>R</sup>

(See Fig. 11)

pTTc  $\omega$  Tet<sup>R</sup>

For yeast: pTy $\omega$ 6 is a pD123 derivative in which the I-SceI site has been inserted in the LTR of the Ty element.

(Fig. 12)

For mammalian cells:

pMLV LTR SAPLZ: containing the I-SceI site in the LTR of MLV and Phleo-LacZ (Fig. 13). This vector is first grown in  $\Psi$ 2 cells (3T3 derivative, from R. Mulligan). Two transgenic cell lines with the I-SceI site at undetermined locations in the genome are available: 1009 (pluripotent nerve cells, J.F. Nicolas) and D3 (ES cells able to generate transgenic animals).

#### 4. The nested chromosomal fragmentation strategy

The nested chromosomal fragmentation strategy for genetically mapping a eukaryotic genome exploits the unique properties of the restriction endonuclease I-SceI, such as an 18 bp long recognition site. The absence of natural I-SceI recognition sites in most eukaryotic genomes is also exploited in this mapping strategy.

First, one or more I-SceI recognition sites are artificially inserted at various positions in a genome, by

The chromosomal fragments are then purified and separated by pulsed field gel (PFG) electrophoresis, allowing one to "map" the position of the inserted site in the chromosome. If total DNA is cleaved with the restriction enzyme, each artificially introduced I-SceI site provides a unique "molecular milestone" in the genome. Thus, a set of transgenic strains, each carrying a single I-SceI site, can be created which defines physical genomic intervals between the milestones. Consequently, an entire genome, a chromosome or any segment of interest can be mapped using artificially introduced I-SceI restriction sites.

The nested chromosomal fragments may be transferred to a solid membrane and hybridized to a labelled probe containing DNA complementary to the DNA of the fragments. Based on the hybridization banding patterns that are observed, the eukaryotic genome may be mapped. The set of transgenic strains with appropriate "milestones" is used as a reference to map any new gene or clone by direct hybridization.

Example 1: Application of the Nested Chromosomal Fragmentation Strategy to the Mapping of Yeast Chromosome XI

This strategy has been applied to the mapping of yeast chromosome XI of *Saccharomyces cerevisiae*. The I-SceI site was inserted at 7 different locations along chromosome XI of the diploid strain FY1679, hence defining eight physical intervals in that chromosome. Sites were inserted from a URA3-1-I-SceI cassette by homologous recombination. Two sites were inserted within genetically defined genes, TIF1 and FAS1, the others were inserted at unknown positions in the chromosome from five non-overlapping cosmids of our library, taken at random. Agarose embedded DNA of each of the seven transgenic strains was then digested with I-SceI and analyzed by pulsed field gel electrophoresis (Fig. 14A). The position of the I-SceI site of each transgenic strain in chromosome XI is first deduced from the fragment sizes without consideration of the left/right orientation of the fragments. Orientation was determined as follows. The most telomere proximal I-SceI site from this set of strains is in the transgenic E40 because the 50 kb fragment is the shortest of all fragments (Fig. 15A). Therefore, the cosmid clone pUKG040, which was used to insert the I-SceI site in the transgenic E40, is now used as a probe against all chromosome fragments (Fig. 14B). As expected, pUKG040 lights up the two fragments from strain E40 (50 kb and 630 kb, respectively). The large fragment is close to the entire chromosome XI and shows a weak hybridization signal due to the fact that the insert of pUKG040, which is 38 kb long, contains less than 4

09493697-012200



kb within the large chromosome fragment. Note that the entire chromosome XI remains visible after I-SceI digestion, due to the fact that the transgenic strains are diploids in which the I-SceI site is inserted in only one of the two homologs. Now, the pUKG040 probe hybridizes to only one fragment of all other transgenic strains allowing unambiguous left/right orientation of I-SceI sites (See Fig. 15B). No significant cross hybridization between the cosmid vector and the chromosome subfragment containing the I-SceI site insertion vector is visible. Transgenic strains can now be ordered such that I-SceI sites are located at increasing distances from the hybridizing end of the chromosome (Fig. 15C) and the I-SceI map can be deduced (Fig. 15D). Precision of the mapping depends upon PFGE resolution and optimal calibration. Note that actual left/right orientation of the chromosome with respect to the genetic map is not known at this step. To help visualize our strategy and to obtain more precise measurements of the interval sizes between I-SceI sites, a new pulsed field gel electrophoresis with the same transgenic strains now placed in order was made (Fig. 16). After transfer, the fragments were hybridized successively with cosmids pUKG040 and pUKG066 which light up, respectively, all fragments from the opposite ends of the chromosome (clone pUKG066 defines the right end of the chromosome as defined from the genetic map because it contains the SIR1 gene. A regular stepwise progression of chromosome fragment sizes is observed. Note some cross

002210 1626460

hybridization between the probe pUKG066 and chromosome III, probably due to some repetitive DNA sequences.

All chromosome fragments, taken together, now define physical intervals as indicated in Fig. 15d. The I-SceI map obtained has an 80 kb average resolution.

### Example 2: Application of the Nested Chromosomal Fragmentation Strategy to the Mapping of Yeast Artificial Chromosome (YAC) Clones

This strategy can be applied to YAC mapping with two possibilities.

-1- insertion of the I-SceI site within the gene of interest using homologous recombination in yeast. This permits mapping of that gene in the YAC insert by I-SceI digestion *in vitro*. This has been done and works.

-2- random integration of I-SceI sites along the YAC insert by homologous recombination in yeast using highly repetitive sequences (e.g., B2 in mouse or Alu in human). Transgenic strains are then used as described in ref. P1 to sort libraries or map genes.

The procedure has now been extended to YAC containing 450 kb of Mouse DNA. To this end, a repeated sequence of mouse DNA (called B2) has been inserted in a plasmid containing the I-SceI site and a selectable yeast marker (LYS2). Transformation of the yeast cells containing the recombinant YAC with the plasmid linearized within the B2 sequence resulted in the integration of the I-SceI site at five different locations distributed along the mouse DNA insert. Cleavage at the inserted I-SceI sites using the

enzyme has been successful, producing nested fragments that can be purified after electrophoresis. Subsequent steps of the protocol exactly parallels the procedure described in Example 1.

Example 3: Application of Nested Chromosomal Fragments to the Direct Sorting of Cosmid Libraries

The nested, chromosomal fragments can be purified from preparative PFG and used as probes against clones from a chromosome X1 specific sublibrary. This sublibrary is composed of 138 cosmid clones (corresponding to eight times coverage) which have been previously sorted from our complete yeast genomic libraries by colony hybridization with PFG purified chromosome X1. This collection of unordered clones has been sequentially hybridized with chromosome fragments taken in order of increasing sizes from the left end of the chromosome. Localization of each cosmid clone on the I-SceI map could be unambiguously determined from such hybridizations. To further verify the results and to provide a more precise map, a subset of all cosmid clones, now placed in order, have been digested with EcoRI, electrophoresed and hybridized with the nested series of chromosome fragments in order of increasing sizes from the left end of the chromosome. Results are given in Figure 17.

For a given probe, two cases can be distinguished: cosmid clones in which all EcoRI fragments hybridize with the probe and cosmid clones in which only some of the EcoRI fragments hybridize (i.e., compare pEKG100 to pEKG098 in Fig.

002710 15926450

17b). The first category corresponds to clones in which the insert is entirely included in one of the two chromosome fragments, the second to clones in which the insert overlaps an I-SceI site. Note that, for clones of the pEKG series, the EcoRI fragment of 8 kb is entirely composed of vector sequences (pWE15) that do not hybridize with the chromosome fragments. In the case where the chromosome fragment possesses the integration vector, a weak cross hybridization with the cosmid is observed (Fig. 17e).

Examination of Fig. 17 shows that the cosmid clones can unambiguously be ordered with respect to the I-SceI map (Fig. 13E), each clone falling either in a defined interval or across an I-SceI site. In addition, clones from the second category allow us to place some EcoRI fragments on the I-SceI maps, while others remain unordered. The complete set of chromosome XI- specific cosmid clones, covering altogether eight times the equivalent of the chromosome, has been sorted with respect to the I-SceI map, as shown in Fig. 18.

##### 5. Partial restriction mapping using I-SceI

In this embodiment, complete digestion of the DNA at the artificially inserted I-SceI site is followed by partial digestion with bacterial restriction endonucleases of choice. The restriction fragments are then separated by electrophoresis and blotted. Indirect end labelling is accomplished using left or right I-Sce half sites. This technique has been successful with yeast chromosomes and should be applicable without difficulty for YAC.

Partial restriction mapping has been done on yeast DNA and on mammalian cell DNA using the commercial enzyme I-SceI. DNA from cells containing an artificially inserted I-SceI site is first cleaved to completion by I-SceI. The DNA is then treated under partial cleavage conditions with bacterial restriction endonucleases of interest (e.g., *Bam*HI) and electrophoresed along with size calibration markers. The DNA is transferred to a membrane and hybridized successively using the short sequences flanking the I-SceI sites on either side (these sequences are known because they are part of the original insertion vector that was used to introduce the I-SceI site). Autoradiography (or other equivalent detection system using non radioactive probes) permit the visualization of ladders, which directly represent the succession of the bacterial restriction endonuclease sites from the I-SceI site. The size of each band of the ladder is used to calculate the physical distance between the successive bacterial restriction endonuclease sites.

Application of I-SceI for *In Vivo*  
Site Directed Recombination

1. Expression of I-SceI in yeast

The synthetic I-SceI gene has been placed under the control of a galactose inducible promoter on multicopy plasmids pPEX7 and pPEX408. Expression is correct and induces effects on site as indicated below. A transgenic yeast with the I-SceI synthetic gene inserted in a chromosome

under the control of an inducible promoter can be constructed.

2. Effects of site specific double strand breaks in yeast (refs. 18 and P4)

Effects on plasmid-borne I-SceI sites:

Intramolecular effects are described in detail in Ref. 18. Intermolecular (plasmid to chromosome) recombination can be predicted.

Effects on chromosome integrated I-SceI sites

In a haploid cell, a single break within a chromosome at an artificial I-SceI site results in cell division arrest followed by death (only a few % of survival). Presence of an intact sequence homologous to the cut site results in repair and 100% cell survival. In a diploid cell, a single break within a chromosome at an artificial I-SceI site results in repair using the chromosome homolog and 100% cell survival. In both cases, repair of the induced double strand break results in loss of heterozygosity with deletion of the non homologous sequences flanking the cut and insertion of the non homologous sequences from the donor DNA molecule.

3. Application for in vivo recombination YACs in Yeast

Construction of a YAC vector with the I-SceI restriction site next to the cloning site should permit one to induce homologous recombination with another YAC if inserts are

09493697-012700

partially overlapping. This is useful for the construction of contigs.

#### 4. Prospects for other organisms

Insertion of an I-SceI restriction site has been done for bacteria (*E. coli*, *Yersinia enterocolitica*, *Y. pestis*, *Y. pseudotuberculosis*), and mouse cells. Cleavage at the artificial I-SceI site *in vitro* has been successful with DNA from the transgenic mouse cells. Expression of I-SceI from the synthetic gene in mammalian or plant cells should be successful.

The I-SceI site has been introduced in mouse cells and bacterial cells as follows:

-1- Mouse cells:

-a- Mouse cells ( $\psi 2$ ) were transfected with the DNA of the vector pMLV LTR SAPLZ containing the I-SceI site using standard calcium phosphate transfection technique.

-b- Transfected cells were selected in DMEM medium containing phleomycin with 5% fetal calf serum and grown under 12% CO<sub>2</sub>, 100% humidity at 37°C until they form colonies.

-c- Phleomycin resistant colonies were subcloned once in the same medium.

-d- Clone MLOP014, which gave a titer of  $10^5$  virus particles per ml, was chosen. This clone was deposited at C.N.C.M. on May 5, 1992 under culture collection accession No. I-1207.

-e- The supernatant of this clone was used to infect other mouse cells (1009) by spreading  $10^5$  virus particles on

002270 16925450

$10^5$  cells in DMEM medium with 10% fetal calf serum and 5 mg/ml of "polybrain". Medium was replaced 6 hours after infection by the same fresh medium.

-f- 24 hours after infection, phleomycin resistant cells were selected in the same medium as above.

-g- phleomycin resistant colonies were subcloned once in the same medium.

-h- one clone was picked and analyzed. DNA was purified with standard procedures and digested with I-SceI under optimal conditions.

-2- Bacterial cells:

Mini Tn 5 transposons containing the I-SceI recognition site were constructed in *E. coli* by standard recombinant DNA procedures. The mini Tn 5 transposons are carried on a conjugative plasmid. Bacterial conjugation between *E. coli* and *Yersinia* is used to integrate the mini Tn 5 transposon in *Yersinia*. *Yersinia* cells resistant to Kanamycin, Streptomycin or tetracycline are selected (vectors pTKM- $\omega$ , pTSM- $\omega$  and pTTc- $\omega$ , respectively).

Several strategies can be attempted for the site specific insertion of a DNA fragment from a plasmid into a chromosome. This will make it possible to insert transgenes at predetermined sites without laborious screening steps.

Strategies are:

-1- Construction of a transgenic cell in which the I-SceI recognition site is inserted at a unique location in a chromosome. Cotransformation of the transgenic cell with the expression vector and a plasmid containing the gene of

002210 26926450



interest and a segment homologous to the sequence in which the I-SceI site is inserted.

-2- Insertion of the I-SceI recognition site next to or within the gene of interest carried on a plasmid.

Cotransformation of a normal cell with the expression vector carrying the synthetic I-SceI gene and the plasmid containing the I-SceI recognition site.

-3- Construction of a stable transgenic cell line in which the I-SceI gene has been integrated in the genome under the control of an inducible or constitutive cellular promoter. Transformation of the cell line by a plasmid containing the I-SceI site next to or within the gene of interest.

Site directed homologous recombination: diagrams of successful experiments performed in yeast are given in Fig. 19.

002210 1502450

### Publications Cited In Application

1. B. Dujon, Sequence of the intron and flanking exons of the mitochondrial 21 S rRNA gene of yeast strains having different alleles at the w and RIB 1 loci. *Cell* (1980) 20, 185-187.
2. F. Michel, A. Jacquier and B. Dujon, Comparison of fungal mitochondrial introns reveals extensive homologies in RNA secondary structure. *Biochimie*, 1982, 64, 867-881.
3. F. Michel and B. Dujon, Conservation of RNA secondary structures in two intron families including mitochondrial-, chloroplast-, and nuclear-encoded members. *The EMBO Journal*, 1983, 2, 33-38.
4. A. Jacquier and B. Dujon, The intron of the mitochondrial 21S rRNA gene: distribution in different yeast species and sequence comparison between *Kluyveromyces thermotolerans* and *Saccharomyces cerevisiae*. *Mol. Gen. Gent.* (1983) 192, 487-499.
5. B. Dujon and A. Jacquier, Organization of the mitochondrial 21S rRNA gene in *Saccharomyces cerevisiae*: mutants of the peptidyl transferase centre and nature of the omega locus in "Mitochondria 1983", Editors R. J. Schweyen, K. Wolf, F. Kaudewitz, Walter de Gruyter et Co., Berlin, New York (1983), 389-403.
6. A. Jacquier and B. Dujon, An intron encoded protein is active in a gene conversion process that spreads an intron into a mitochondrial gene. *Cell* (1985) 41, 383-394.

7. B. Dujon, G. Cottarel, L. Colleaux, M. Betermier, A. Jacquier, L. D'Auriol, F. Galibert, Mechanism of integration of an intron within a mitochondrial gene: a double strand break and the transposase function of an intron encoded protein as revealed by *in vivo* and *in vitro* assays. In "Achievements and perspectives of Mitochondrial Research". Vol. II, Biogenesis, E. Quagliariello et al. Eds. Elsevier, Amsterdam (1985) pages 215-225.
8. L. Colleaux, L. D'Auriol, M. Betermier, G. Cottarel, A. Jacquier, F. Galibert, and B. Dujon, A universal code equivalent of a yeast mitochondrial intron reading frame is expressed into *Escherichia coli* as a specific double strand endonuclease. *Cell* (1986) 44, 521-533.
9. B. Dujon, L. Colleaux, A. Jacquier, F. Michel and C. Monteilhet, Mitochondrial introns as mobile genetic elements: the role of intron-encoded proteins. In "Extrachromosomal elements in lower eucaryotes", Reed B et al. Eds. (1986) Plenum Pub. Corp. 5-27.
10. F. Michel and B. Dujon, Genetic Exchanges between Bacteriophage T4 and Filamentous Fungi? *Cell* (1986) 46, 323.
11. L. Colleaux, L. D'Auriol, F. Galibert and B. Dujon, Recognition and cleavage site of the intron encoded omega transposase. *PNAS* (1988), 85, 6022-6026.
12. B. Dujon, Group I introns as mobile genetic elements, facts and mechanistic speculations: A Review. *Gene* (1989), 82, 91-114.

- [illegible]

Abstracts

- A1. A. Jacquier, B. Dujon. Intron recombinational insertion at the DNA level: Nature of a specific receptor site and direct role of an intron encoded protein. Cold Spring Harbor Symposium 1984.
- A2. I. Colleaux, L. D'Auriol, M. Demariaux, B. Dujon, F. Galibert, and A. Jacquier, Construction of a universal code equivalent from a mitochondrial intron encoded transposase gene using oligonucleotide directed multiple mutagenesis. Colloque International de DNRS "oligonucleotids et Genetique Moleculaire" Aussois (Savoie) 8-12 January 1985.
- A3. L. Colleaux, D'Auriol, M. Demariaux, B. Dujon, F. Galibert, and A. Jacquier, Expression in E. coli of a universal code equivalent of a yeast mitochondrial intron reading frame involved in the integration of an intron within a gene. Cold Spring Harbor Meeting on "Molecular Biology of Yeast", August 13-19, 1985.
- A4. B. Dujon, G. Cottarel, L. Colleaux, M. Demariaux, A. Jacquier, L. D'Auriol, and F. Galibert, Mechanism of integration of an intron within a mitochondrial gene: a double strand break and the "transposase" function of an intron encoded protein as revealed by *in vivo* and *in vitro* assays. International symposium on "Achievements and Perspectives in Mitochondrial Research", Selva de Fasano (Brindisi, Italy) 26 September 1985.
- A5. L. Colleaux, G. Cottarel, M. Betermier, A. Jacquier, B. Dujon, L. D'auriol, and F. Galibert, Mise en evidence de

00493697 012700

l'activite endonuclease double brin d'unc protein codee par un intron mitochondrial de levure. Forum sur la Biologie Moleculaire de la levure, Bonbannes, France 2-4 October 1985.

- A6. B. Dujon, L. Colleaux, F. Michel and A. Jacquier, Mitochondrial introns as mobile genetic elements. In "Extrachromosomal elements in lower eucaryotes", Urbana, Illinois, 1-5 June 1986.
- A7. L. Colleaux and B. Dujon, Activity of a mitochondrial intron encoded transposase. Yeast Genetics and Molecular Biology Meeting, Urbana, Illinois 3-6 June 1986.
- A8. L. Colleaux and B. Dujon, The role of a mitochondrial intron encoded protein. XIIIth International Conference on Yeast Genetics and Molecular Biology, Banff, Alberta (Canada) 31 August - 5 September 1986.
- A9. L. Colleaux, L. D'Aurio, F. Galibert and and B. Dujon, Recognition and cleavage specificity of an intron encoded transposase. 1987 Meeting on Yeast Genetics and Molecular Biology. San Francisco, CA 16-21 June 1987.
- A10. A. Perrin, C. Monteilhet, L. Colleaux and B. Dujon, Biochemical activity of an intron encoded transposase of *Saccharomyces cerevisiae*. Cold Spring Harbor Meeting on "Molecular Biology of Mitochondria and chloroplasts" 25-30 August 1987 Cold Spring Harbor, N.Y.
- A11. B. Dujon, A. Jacquier, L. Colleaux, C. Monteilhet, A. Perrin, "Les Introns autoepissables et leurs proteins" Colloque "Biologie Moleculaire de la levure: expression genetique chez *Saccharomyces* "organise par la Societe

francaise de Microbiologie 18 January 1988 Institut  
Pasteur, Paris.

- A12. L. Colleaux, L. D'Auriol, C. Monteilhet, F. Galibert and  
B. Dujon, Characterization of the biochemical activity  
of an intron encoded transposase. 14th International  
Conference on Yeast Genetics and Molecular Biology.  
Espoo, Finland, 7-13 August 1988.
- A13. B. Dujon, A group I intron as a mobile genetic element,  
Albany Conference sur "RNA: catalysis, splicing,  
evolution", Albany, New York, 22-25 September 1988.
- A14. B. Dujon, L. Colleaux, C. Monteilhet, A. Perrin, L.  
D'Auriol, F. Galibert, Group I introns as mobile genetic  
elements: the role of intron encoded proteins and the  
nature of the target site. 14th Annual EMBO Symposium  
"Organelle genomes and the nucleus" Heidelberg, 26-29  
September 1988.
- A15. L. Colleaux, R. Matagne, B. Dujon, A new mobile mito-  
chondrial intron provides evidence for genetic exchange  
between Neurospora and Chlamydomonas species. Cold  
Spring Harbor, May 1989.
- A16. L. Colleaux, M.R. Michel-Wolwertz, R.F. Matagne, B.  
Dujon, The apoxytochrome b gene of Chlamydomonas smithii  
contains a mobile intron related to both Saccharomyces  
and Neurospora introns. Fourth International Conference  
on Cell and Molecular Biology of Chlamydomonas.  
Madison, WI, April 1990.

002270" 013700

- A17. B. Dujon, L. Colleaux, E. Luzi, C. Monteilhet, A. Perrin, A. Plessis, I. Stroke, A. Thierry, Mobile Introns, EMBO Workshop on "Molecular Mechanisms of transposition and its control, Roscoff (France) June 1990.
- A18. A. Perrin, C. Monteilhet, A. Thierry, E. Luzi, I. Stroke, L. Colleaux, B. Dujon. I-SceI, a novel double strand site specific endonuclease, encoded by a mobile group I intron in Yeast. Workshop on "RecA and Related Proteins" Sacly, France 17-21 September 1990.
- A19. A. Plessis, A. Perrin, B. Dujon, Site specific recombination induced by double strand endonucleases, HO and I-SceI in yeast. Workshop on "RecA and Related Proteins" Saclay, France 17-21 September 1990.
- A20. B. Dujon, The genetic propagation of introns 20th FEBS Meeting, Budapest, Hungary, August 1990.
- A21. E. Luzi, B. Dujon, Analysis of the intron encoded site specific endonuclease I-SceI by mutagenesis, Third European Congress on Cell Biology, Florence, Italy, September 1990.
- A22. B. Dujon, Self splicing introns as contagious genetic elements. Journees Franco-Beiges de Pont a Mousson. October 1990.
- A23. B. Frey, H. Dubler, G. Schmitz, A. Thierry, A. Perrin, J. Boyer, C. Fairhead, B. Dujon, Specific cleavage of the yeast genome at a single site using the rare cutter endonuclease I-SceI Human Genome, Frankfurt, Germany, November 1990.



- A24. B. Dujon, A. Perrin, I. Stroke, E. Luzi, L. Colleaux, A. Plessis, A. Thierry, The genetic mobility of group I introns at the DNA level. Keystone Symposia Meeting on "Molecular Evolution of Introns and Other RNA elements", Taos, New Mexico, 2-8 February 1991.
- A25. B. Dujon, J. Boyer, C. Fairhead, A. Perrin, A. Thierry, Cartographie chez la levure. Reunion "Strategies d'etablissement des cartes geniques" Toulouse 30-31 Mai 1991.
- A26. B. Dujon, A. Thierry, Nested chromosomal fragmentation using the meganuclease I-SceI: a new method for the rapid mapping of the yeast genome. Elounda, Crete 15-17 Mail 1991.
- A27. A. Thierry, L. Gaillon, F. Galibert, B. Dujon. The chromosome XI library: what has been accomplished, what is left. Brugge meeting 22-24 September 1991.
- A28. B. Dujon, A. Thierry, Nested chromosomal fragmentation using the meganuclease I-SceI: a new method for the rapid physical mapping of the eukaryotic genomes. Cold Spring Harbor 6-10 May 1992.
- A29. A. Thierry, L. Gaillon, F. Galibert, B. Dujon. Yeast chromosome XI: construction of a cosmid contig. a high resolution map and sequencing progress. Cold Spring Harbor 6-10 May 1992.

In Preparation

- P1. A. Thierry and B. Dujon, Nested Chromosomal Fragmentation Using the Meganuclease I-SceI: Application to the

004939-012700 00/210/26926460

physical mapping of a yeast chromosome and the direct sorting of cosmid libraries. Probably Submission to GENOMICS or EMBO J.

- P2. A. Thierry, L. Colleaux and B. Dujon: Construction and Expression of a synthetic gene coding for the meganuclease I-SceI. Possible submission: NAR, EMBO J.
- P3. I. Stroke, V. Pelicic and B. Dujon: The evolutionarily conserved dodecapeptide motifs of intron-encoded I-SceI are essential for endonuclease function. Submission to EMBO J.
- P4. C. Fairhead and B. Dujon: Consequences of a double strand break induced *in vivo* in yeast at specific artificial sites, using the meganuclease I-SceI. Possible submission to GENETICS, NATURE.
- P5 A. Perrin, and B. Dujon: Asymmetrical recognition by the I-SceI endonuclease on exon and intron sequences reveals a new step in intron mobility. Possible submission: NATURE

The entire disclosure of all publications and abstracts cited herein is incorporated by reference herein.

Induction of homologous recombination in mammalian  
chromosomes using the I-Sce I system of *Saccharomyces  
cerevisiae*

Example 4

INTRODUCTION

Homologous recombination (HR) between chromosomal and exogenous DNA is at the basis of methods for introducing genetic changes into the genome (5B, 20B). Parameters of the recombination mechanism have been determined by studying plasmid sequences introduced into cells (1B, 4B, 10B, 12B) and in *in vitro* system (8B). HR is inefficient in mammalian cells but is promoted by double-strand breaks in DNA.

So far, it has not been possible to cleave a specific chromosomal target efficiently, thus limiting our understanding of recombination and its exploitation. Among endonucleases, the *Saccharomyces cerevisiae* mitochondrial endonuclease I-Sce I (6B) has characteristics which can be exploited as a tool for cleaving a specific chromosomal target and, therefore, manipulating the chromosome in living organisms. I-Sce I protein is an endonuclease responsible for intron homing in mitochondria of yeast, a non-reciprocal mechanism by which a predetermined sequence becomes inserted at a predetermined site. It has been established that endonuclease I-Sce I can catalyze recombination in the nucleus of yeast by initiating a double-strand break (17B). The recognition site of endonuclease I-Sce I is 18 bp long, therefore, the I-Sce I protein is a very rare cutting restriction endonuclease in genomes (22B). In addition, as the I-Sce I protein is not a recombinase, its potential for chromosome

engineering is larger than that of systems with target sites requirement on both host and donor molecules (9B).

We demonstrate here that the yeast I-Sce I endonuclease can efficiently induce double-strand breaks in chromosomal target in mammalian cells and that the breaks can be repaired using a donor molecule that shares homology with the regions flanking the break. The enzyme catalyzes recombination at a high efficiency. This demonstrates that recombination between chromosomal DNA and exogenous DNA can occur in mammalian cells by the double-strand break repair pathway (21B).

## MATERIALS AND METHODS

### Plasmid construction

pG-MPL was obtained in four steps: (I) insertion of the 0.3 kb *Bgl* II - *Sma* I fragment (treated with Klenow enzyme) of the Moloney Murine Leukemia Virus (MoMuLV) *env* gene (25B) containing SA between the *Nhe* I and *Xba* I sites (treated with Klenow enzyme), in the U3 sequence of the 3'LTR of MoMuLV, in an intermediate plasmid. (II) insertion in this modified LTR with linkers adaptors of the 3.5 kb *Nco* I - *Xho* I fragment containing the *PhleoLacZ* fusion gene (15B) (from pUT65 from Cayla laboratory) at the *Xba* I site next to SA. (III) insertion of this 3'LTR (containing SA and *PhleoLacZ*), recovered by *Sal* I - *EcoR* I double digestion in p5'LTR plasmid (a plasmid containing the 5'LTR to the nucleotide number 563 of MoMuLV (26B) between the *Xho* I and the *EcoR* I sites, and (VI) insertion of a synthetic I-Sce I recognition site into the *Nco* I site in the 3'LTR (between SA and *PhleoLacZ*).

pG-MtkPl was obtained by the insertion (antisense to the retroviral genome) of the 1.6 kb *tk* gene with its promoter with linker adaptators at the *Pst* I site of pG-MPL. pVRneo was obtained in two steps (I) insertion into pSP65 (from Promega) linearized by *Pst* I - *EcoR* I double digestion of the 4.5 kb *Pst* I to *EcoR* I fragment of pG-MPL containing the 3'LTR with the SA and *PhleoLacZ*, (II) insertion of the 2.0 kb *Bgl* II - *BamH* I fragment (treated with Klenow enzyme) containing neoPolyA from pRSVneo into the *Nco* I restriction site (treated with Klenow enzyme) of pSP65 containing part of the 3'LTR of G-MPL (between SA and *PhleoLacZ*).

pCMV(I-Sce I+) was obtained in two steps: (I) insertion of the 0.73 kb *BamH* I - *Sal* I, I-Sce I containing fragment (from pSCM525, A. Thierry, personal gift) into the phCMV1 (F. Meyer, personal gift) plasmid cleaved at the *BamH* I and the *Sal* I sites, (II) insertion of a 1.6 kb (nucleotide number 3204 to 1988 in SV40) fragment containing the polyadenylation signal of SV40 into the *Pst* I site of phCMV1.

pCMV(I-Sce I-) contains the I-Sce I ORF in reverse orientation in the pCMV(I-Sce I+) plasmid. It has been obtained by inserting the *BamH* I - *Pst* I I-Sce I ORF fragment (treated with Klenow enzyme) into the phCMV PolyA vector linearized by *Nsi* I and *Sal* I double-digestion and treated with Klenow enzyme.

Plasmids pG-MPL, pG-MtkPl, pG-Mtk $\Delta$ PAPL have been described. In addition to the plasmids described above, any kind of plasmid vector can be constructed containing various promoters, genes, polyA site, I-Sce I site.

### Cell culture and selection

3T3, PCC7 S,  $\psi$  2 are referenced in (7B) and (13B). Cell selection medium: gancyclovir (14B, 23B) was added into the tissue culture medium at the concentration of  $2\mu\text{M}$ . Gancyclovir selection was maintained on cells during 6 days. G418 was added into the appropriate medium at a concentration of 1 mg/ml for PCC7-S and  $400\mu\text{g/ml}$  for 3T3. The selection was maintained during all the cell culture. Phleomycin was used at a concentration of  $10\mu\text{g/ml}$ .

### Cell lines

-  $\psi$  cell line was transfected with plasmids containing a proviral recombinant vector that contain I-Sce I recognition site: pG-MPL, pG-MtkPL, pG-Mtk $\Delta_{\text{PA}}$ PL

- NIH 3T3 Fibroblastic cell line is infected with:

**G-MPL.** Multiple (more than 30) clones were recovered. The presence of 1 to 14 proviral integrations and the multiplicity of the different points of integration were verified by molecular analysis.

**G-MtkPL.** 4 clones were recovered (3 of them have one normal proviral integration and 1 of them have a recombination between the two LTR so present only one I-Sce I recognition site).

- **Embryonal carcinoma** PCC7-S cell line is infected with:

**G-MPL.** 14 clones were recovered, normal proviral integration.

- **Embryonic stem cell** line D3 is infected with:

**G-MPL.** 4 clones were recovered (3 have normal proviral integration, 1 has 4 proviral integrations).

09492697 "012700

**"Prepared" mouse cells:**

Insertion of the retrovirus (proviral integration) induces duplication of LTR containing the I-Sce I site. The cell is heterozygotic for the site.

**Transfection, infection, cell staining  
and nucleic acids blot analysis**

These procedures were performed as described in (2B, 3B).

**RESULTS**

To detect I-Sce I HR we have designed the experimental system shown in Fig. 20. Defective recombinant retroviruses (24B) were constructed with the I-Sce I recognition site and a *PhleoLacZ* (15B) fusion gene inserted in their 3'LTR (Fig. 20a). Retroviral integration results in two I-Sce I sites distant of 5.8 kb or 7.2 kb from each other into the cell genome (Fig. 20b). We hypothesized that I-Sce I-induced double-strand breaks (DSB) at these sites (Fig. 20c) could initiate HR with a donor plasmid (pVRneo, Fig. 20d) containing sequences homologous to the flanking regions of the DSBs and that non-homologous sequences, carried by the donor plasmid, could be copied during this recombination (Fig. 20e).

**Introduction of duplicated I-Sce I recognition sites into the  
genome of mammalian cells by retrovirus integration**

More specifically, two proviral sequences were used in these studies. The G-MtkPL proviral sequences (from G-MtkPL virus) contain the *PhleoLacZ* fusion gene for positive selection of transduced cells (in phleomycine-containing medium) and the *tk* gene for negative selection (in gancyclovir-containing medium).

The G-MPL proviral sequences (from G-MPL virus) contain only the *PhleoLacZ* sequences. G-MtkPL and G-MPL are defective recombinant retroviruses (16B) constructed from an enhancerless Moloney murine leukemia provirus. The virus vector functions as a promoter trap and therefore is activated by flanking cellular promoters.

Virus-producing cell lines were generated by transfecting pG-MtkPL or G-MPL into the  $\psi$ -2 package cell line (13B). Northern blot analysis of viral transcripts shows (Fig. 21) that the  $\psi$ -2-G-MPL line expresses 4.2 and 5.8 kb transcripts that hybridized with LacZ probes. These transcripts probably initiate in the 5'LTR and terminate in the 3'LTR. The 4.5 kb transcript corresponds to the spliced message and the 5.8 kb transcripts to the unspliced genomic message (Fig. 21.A). This verified the functionality of the 5'LTR and of the splice donor and acceptor in the virus. Similar results have been obtained with  $\psi$ -2G-MtkPL. Virus was prepared from the culture medium of  $\psi$ -2 cell lines.

NIH3T3 fibroblasts and PCC7-S multipotent mouse cell lines (7B) were next infected by G-MtkPL and G-MPL respectively, and clones were isolated. Southern blot analysis of the DNA prepared from the clones demonstrated LTR-mediated duplication of I-Sce I *PhleoLacZ* sequences (Fig. 22.a). *Bcl* I digestion generated the expected 5.8 kb (G-MPL) or 7.2 kb (G-MtkPL) fragments. The presence of two additional fragments corresponding to *Bcl* I sites in the flanking chromosomal DNA demonstrates a single proviral target in each clone isolated. Their variable size from clone to clone indicates integration of retroviruses at distinct loci.



That I-Sce I recognition sites have been faithfully duplicated was shown by I-Sce I digests which generated 5.8 kb (G-MPL) fragments or 7.2 kb (G-MtkPL) (Fig. 22.b)

#### **Induction by I-Sce I of recombination leading to DNA exchange**

The phenotype conferred to the NIH3T3 cells by G-MtkPL virus is  $\text{phleo}^R \beta\text{-gal}^+ \text{gls}^S$  and to PCC7-S by G-MPL is  $\text{phleo}^R \beta\text{-gal}^+$  (Fig. 20b). To allow for direct selection of recombination events induced by I-Sce I we constructed pVRneo donor plasmid. In pVRneo the neo gene is flanked by 300 bp homologous to sequences 5' to the left chromosomal break and 2.5 kb homologous to sequences 3' to the right break (Fig. 20d). A polyadenylation signal was positioned 3' to the neo gene to interrupt the *PhleoLacZ* message following recombination. If an induced recombination between the provirus and the plasmid occurs, the resulting phenotype will be  $\text{neo}^R$  and due to the presence of a polyadenylation signal in the donor plasmid the *PhleoLacZ* gene should not be expressed, resulting in a  $\text{phleo}^S \beta\text{-gal}^-$  phenotype.

With G-MtkPL and G-MtkDPQPL, it is possible to select simultaneously for the gap by negative selection with the tk gene (with gancyclovir) and for the exchange of the donor plasmid with positive selection with the neo gene (with geneticine). With G-MPL only the positive selection can be applied in medium containing geneticine. Therefore, we expected to select for both the HR and for an integration event of the donor plasmid near an active endogenous promoter. These two events can be distinguished as an induced HR results in a  $\text{neo}^R \beta\text{-gal}^-$  phenotype and a random integration of the donor plasmid results in a  $\text{neo}^R \beta\text{-gal}^+$  phenotype.

Two different NIH3T3/G-MtkPL and three different PCC7S/G-MPL clones were then co-transfected with an expression vector for I-Sce I, pCMV(I-Sce I+), and the donor plasmid, pVRneo. Transient expression of I-Sce I may result in DSBs at I-Sce I sites, therefore promoting HR with pVRneo. The control is the co-transfection with a plasmid which does not express I-Sce I, pCMV(I-Sce I-), and pVRneo.

NIH3T3/G-MtkPL clones were selected either for loss of proviral sequences and acquisition of the neo<sup>R</sup> phenotype (with gancyclovir and geneticine) or for neo<sup>R</sup> phenotype only (Table 1). In the first case, neo<sup>R</sup>gls<sup>R</sup> colonies were recovered with a frequency of 10<sup>-4</sup> in experimental series, and no colonies were recovered in the control series. In addition, all neo<sup>R</sup>gls<sup>R</sup> colonies were  $\beta$ -gal<sup>-</sup>, consistent with their resulting from HR at the proviral site. In the second case, neo<sup>R</sup> colonies were recovered with a frequency of 10<sup>-3</sup> in experimental series, and with a 10 to 100 fold lower frequency in the control series. In addition, 90% of the neo<sup>R</sup> colonies were found to be  $\beta$ -gal<sup>-</sup> (in series with pCMV(I-Sce I+)). This shows that expression of I-Sce I induces HR between pVR neo and the proviral site and that site directed HR is ten times more frequent than random integration of pVR neo near a cellular promoter, and at least 500 times more frequent than spontaneous HR.

Table 1. Induced homologous recombination with I-Sce I

Selection	G418 + Gls				G418			
	+		-		+		-	
I-Sce I expression								
$\beta$ -gal phenotype	+	-	+	-	+	-	+	-
(A) Cell line								
NIH 3T3/G-MtkPL								
Clone 1	0	66	0	0	69	581	93	0
Clone 2	0	120	0	0	15	742	30	0
PCC7-S/G-MPL								
Clone 3					54	777	7	0
Clone 4					2	91	1	0
Clone 5					7	338	3	0
(B) Molecular event								
RI	0				8	1	6	
DsHR	15				0	19	0	
SsHR	0				0	4	0	
Del	0				0	1	0	

**TABLE 1:** Effect of I-Sce I mediated double-strand cleavage. A.  $10^6$  cells of NIH3T3/G-MtkPL clones 1 and 2 and  $5 \cdot 10^6$  cells of PCC7-S/G-MPL clones 3 to 5 were co-transfected with pVRneo and either pCMV(I-Sce I+) or pCMV(I-Sce I-). Cells were selected in the indicated medium: Geneticin (G418) or geneticin + gancyclovir (G418\_Gls). The  $\beta$ -gal expression phenotype was determined by X-gal histochemical staining. If an induced recombination between the provirus and pVRneo occurs, the cells acquire a  $\text{neo}^R \beta\text{-gal}^-$  phenotype. B. Molecular analysis of a sample of recombinant clones. RI: random integration of pVRneo, parental proviral structure. DsHR: double site HR. SsHR: single site HR. Del: deletion of the provirus (see also Fig. 20 and 23).

#### Verification of recombination by Southern and Northern blot analysis

The molecular structure of  $\text{neo}^R$  recombinants has been examined by Southern blot analysis (Fig. 23 and Table 1). HR at I-Sce I sites predicts that digestion of recombinant DNA generates a 6.4 kb *LacZ* fragment instead of the 4.2kb parental fragment.

All 15  $\text{neo}^R \text{gls}^R \beta\text{-gal}^-$  recombinants from NIH3T3 cells exhibited only the 6.4 kb *Kpn* I fragment. Therefore, the double selection procedure leads to only the expected recombinants created by gene replacement (Double Site Homologous Recombinants, DSHR).

The 25  $\beta\text{-gal}^-$  recombinants generated from the single selection fell into four classes: (a) DSHR induced by I-Sce I as above (19 clones); (b) integration of pVRneo in the left LTR as proven by the presence of a 4.2 *Kpn* I fragment (corresponding to *PhleoLacZ* in the remaining LTR), in addition to the 6.4 kb fragment (Fig. 23, Table 1, Single site Homologous Recombinants, SsHR; 3 independent  $\beta\text{-gal}^-$  recombinants from clone 3). These clones correspond to I-Sce I-IHR in left DSB only or (less likely) to double crossing over between LTR and pVRneo; (c) random pVRneo integrations (Table 1, Random Integrations, IR) and simultaneous HR (Table 1, Deletion, Del) (1  $\beta\text{-gal}^-$  recombinant); and (d) Random pVRneo integration and simultaneous deletion of provirus (1  $\beta\text{-gal}^-$  recombinant). We suggest that this fourth class corresponds to repair of DSBs with the homologous chromosome. As expected, all  $\beta\text{-gal}^+$  recombinants from geneticin selection alone, correspond to random pVRneo integrations, whether they originate from the experimental series (eight clones analyzed) or from the control series (six clones analyzed).

We obtained additional evidence that recombination had occurred at the I-Sce I site of PCC7-S/G-MPL 1 by analyzing the RNAs produced in the parental cells and in the recombinant (Fig. 24). Parental PCC7-S/G-MPL 1 cells express a 7.0 kb *LacZ* RNA indicative of trapping of a cellular promoter leading to

expression of a cellular-viral fusion RNA. The recombinant clone does not express this LacZ RNA but expresses a neo RNA of 5.0 kb. The size of the neo RNA corresponds to the exact size expected for an accurate exchange of *PhleoLacZ* by neo gene and uses of the same cellular and viral splice site (viral *PhleoLacZ* RNA in the LTR is 3.7 kb and neo RNA in pVRneo is 1.7 kb).

## DISCUSSION

The results presented here demonstrate that double-strand breaks can be induced by the I-Sce I system of *Saccharomyces cerevisiae* in mammalian cells, and that the breaks in the target chromosomal sequence induce site-specific recombination with input plasmidic donor DNA.

To operate in mammalian cells, the system requires endogenous I-Sce I like activity to be absent from mammalian cells and I-Sce I protein to be neutral for mammalian cells. It is unlikely that endogenous I-Sce I-like actively operates in mammalian cells as the introduction of I-Sce I recognition sites do not appear to lead to rearrangement or mutation in the input DNA sequences. For instance, all NIH3T3 and PCC7-S clones infected with a retroviruses containing the I-Sce I restriction site stably propagated the virus. To test for the toxicity of I-Sce I gene product, an I-Sce I expressing plasmid was introduced into the NIH3T3 cells line (data not shown). A very high percentage of cotransfer of a functional I-Sce I gene was found, suggesting no selection against this gene. Functionality of I-Sce I gene was demonstrated by analysis of transcription, by immunofluorescence

007270 26926460

detection of the gene product and biological function (Choulika et al. in preparation).

We next tested whether the endonuclease would cleave a recognition site placed on a chromosome. This was accomplished by placing two I-Sce I recognition sites separated by 5.8 or 7.2 kb on a chromosome in each LTR of proviral structures and by analyzing the products of a recombination reaction with a targeting vector in the presence of the I-Sce I gene product. Our results indicate that in presence of I-Sce I, the donor vector recombines very efficiently with sequences within the two LTRs to produce a functional neo gene. This suggests that I-Sce I induced very efficiently double strand breaks in both I-Sce I sites. In addition, as double strand breaks were obtained with at least five distinct proviral insertions, the ability of I-Sce I protein to digest an I-Sce I recognition site is not highly dependent on surrounding structures.

The demonstration of the ability of the I-Sce I meganuclease to have biological function on chromosomal sites in mammalian cell paves the route for a number of manipulations of the genome in living organisms. In comparison with site-specific recombinases (9B, 18B), the I-Sce I system is non-reversible. Site specific recombinases locate not only the sites for cutting the DNA, but also for rejoining by bringing together the two partners. In contrast, the only requirement with the I-Sce I system is homology of the donor molecule with the region flanking the break induced by I-Sce I protein.

The results indicate for the first time that double strand DNA breaks in chromosomal targets stimulate HR with introduced DNA

in mammalian cells. Because we used a combination of double strand breaks (DSB) in chromosomal recipient DNA and super-coiled donor DNA, we explored the stimulation by I-Sce I endonuclease of recombination by the double strand break repair pathway (21B). Therefore, the induced break is probably repaired by a gene conversion event involving the concerted participation of both broken ends which, after creation of single-stranded region by 5' to 3' exonucleolytic digestion, invade and copy DNA from the donor copy. However, a number of studies of recombination in mammalian cells and in yeast (10B, 11B, 19B) suggest that there is an alternative pathway of recombination termed single-strand annealing (SSA). In the SSA pathway, double-strand breaks are substrates in the action of an exonuclease that exposes homologous complementary single-strand DNA on the recipient and donor DNA. Annealing of the complementary strand is then followed by a repair process that generates recombinants. The I-Sce I system can be used to evaluate the relative importance of the two pathways.

#### Example 5

This example describes the use of the I-Sce I meganuclease (involved in intron homing of mitochondria of the yeast *Saccharomyces cerevisiae*) (6B, 28B) to induce DSB and mediate recombination in mammalian cells. I-Sce I is a very rare-cutting restriction endonuclease, with an 18 bp long recognition site (29B, 22B). *In vivo*, I-Sce I endonuclease can induce recombination in a modified yeast nucleus by initiating a specific DSB leading to gap repair by the cell (30B, 17B, 21B). Therefore, this approach can potentially be used as a means of introducing

specific DSB in chromosomal target DNA with a view to manipulate chromosomes in living cells. The I-Sce I-mediated recombination is superior to recombinase system [11] for chromosome engineering since the latter requires the presence of target sites on both host and donor DNA molecules, leading to reaction that is reversible.

The I-Sce I endonuclease expression includes recombination events. Thus, I-Sce I activity can provoke site-directed double strand breaks (DSBs) in a mammalian chromosome. At least two types of events occur in the repair of the DSBs, one leading to intra-chromosomal homologous recombination and the other to the deletion of the transgene. These I-Sce I-mediated recombinations occur at a frequency significantly higher than background.

## MATERIALS AND METHODS

### Plasmid construction

pG-MtkPL was obtained in five steps: (I) insertion of the 0.3 kbp *Bgl* II-*Sma* I fragment (treated with Klenow enzyme) of the Moloney Murine Leukemia Virus (MoMuLV) *env* gene (25B) containing a splice acceptor (SA) between the *Nhe* I and *Xba* I sites (treated with Klenow enzyme), in the U3 sequence of the 3'LTR of MoMuLV, in an intermediate plasmid. (II) Insertion in this modified LTR of a 3.5 kbp *Nco* I-*Xho* I fragment containing the *PhleoLacZ* fusion gene [13] (from pUT65; Cayla Laboratory, Zone Commerciale du Gros, Toulouse, France) at the *Xba* I site next to SA. (III) Insertion of this 3'LTR (containing SA and *PhleoLacZ*), recovered by *Sal* I-*EcoR* I double digestion in the p5'LTR plasmid (a plasmid containing the 5'LTR up to the nucleotide n° 563 of MoMuLV [12])



between the *Xho* I and the *EcoR* I site. (IV) Insertion of a *synthetic* I-Sce I recognition site into the *Nco* I site in the 3'LTR (between SA and *PhleoLacZ*), and (V) insertion (antisense to the retroviral genome) of the 1.6 kbp *tk* gene with its promoter with linker adaptators at the *Pst* I site of pG-MPL.

pCMV(I-Sce I+) was obtained in two steps: (I) insertion of the 0.73 kbp *BamH* I-*Sal* I, I-Sce I-containing fragment (from pSCM525, donated by A. Thierry) into the phCMV1 (donated by F. Meyer) plasmid cleaved with *BamH* I and *Sal* I, (II) insertion of a 1.6 kbp fragment (nucleotide n° 3204 to 1988 in SV40) containing the polyadenylation signal of SV40 at the *Pst* I site of phCMV1.

pCMV(I-Sce I-) contains the I-Sce I ORF in reverse orientation in the pCMV(I-Sce I+) plasmid. It was obtained by inserting the *BamH* I-*Pst* I I-Sce I ORF fragment (treated with Klenow enzyme) into the phCMV PolyA vector linearized by *Nsi* I and *Sal* I double-digestion and treated with Klenow enzyme.

#### Cell culture and selection

T3 and  $\psi$  2 are referenced in (7B) and (13B). Cell selection medium: gancyclovir (14B, 23B) was added into the tissue culture medium at the concentration of 2 $\mu$ M. Gancyclovir selection was maintained for 6 days. Phleomycine was used at a concentration of 10 $\mu$ g/ml. Double selections were performed in the same conditions.

#### Transfection, infection, cell staining and nucleic acids blot analysis

These protocols were performed as described in (2B, 3B).

09492697-012200

### Virus-producing cell lines

The virus-producing cell line is generated by transfecting pG-MtkPL into the  $\psi$ -2 packaging cell line. Virus was prepared from the filtered culture medium of transfected  $\psi$ -2 cell lines. NIH3T3 fibroblasts were infected by G-MtkPL, and clones were isolated in a Phleomycin-containing medium.

### RESULTS

To assay for I-Sce I endonuclease activity in mammalian cells, NIH3T3 cells containing the G-MtkPL provirus were used. The G-MtkPL provirus (Fig. 25a) contains the tk gene (in place of the gag, pol and env viral genes), for negative selection in gancyclovir-containing medium and, in the two LTRs, an I-Sce I recognition site and the *PhleoLacZ* fusion gene. The *PhleoLacZ* gene can be used for positive selection of transduced cells in phleomycine-containing medium.

We hypothesized that the expression of I-Sce I endonuclease in these cells would induce double-strand breaks (DSB) at the I-Sce I recognition sites that would be repaired by one of the following mechanisms (illustrated in Fig. 25): a) if the I-Sce I endonuclease induces a cut in only one of the two LTRs (Fig. 1-b 1 and 2), sequences that are homologous between the two LTRs could pair and recombine leading to an intra-chromosomal homologous recombination (i.e. by single strand annealing (SSA) (12B, 10B) or crossing-over); b) If the I-Sce I endonuclease induces a cut in each of the two LTRs, the two free ends can religate (end joining mechanism (31B) leading to an intra-chromosomal recombination (Fig. 25-b 3); or alternatively c)

the gap created by the two DSBs can be repaired by a gap repair mechanism using sequences either on the homologous chromosome or on other chromosomal segments, leading to the loss of the proviral sequences (32B) (Fig. 25-c).

The phenotype conferred to the NIH3T3 cells by the G-MtkPL provirus is Phleo<sup>R</sup>β-Gal<sup>+</sup> GlS<sup>-S</sup>. In a first series of experiments, we searched for recombination by selecting for the loss of the *tk* gene. NIH3T3/G-MtkPL 1 and 2 (two independent clones with a different proviral integration site) were transfected with the I-Sce I expression vector pCMV(I-Sce I+) or with the control plasmid pCMV(I-Sce-) which does not express the I-Sce I endonuclease. The cells were then propagated in Gancyclovir-containing medium to select for the loss of *tk* activity. The resulting GlS<sup>R</sup> clones were also assayed for β-galactosidase activity by histochemical staining (with X-gal) (Table 1).

Table 1

Number and nature of GlS resistant clones

I-Sce I expression β-Gal activity	pCMV(I-SceI+)		pCMV(I>SceI-)	
	+	-	+	-
NIH3T3/G-MtkPL 1	11	154	0	0
NIH3T3/G-MtkPL 2	16	196	2	0

TABLE 1: Effect of I-Sce I expression on recombination frequency. 1X10<sup>6</sup> cells of NIH3T3/G-MtkPL 1 and 2X10<sup>6</sup> cells of NIH3T3/G-MtkPL 1 were transfected with either pCMV(I-Sce I+) or

pCMV(I-Sce I-). Cells were cultivated in medium containing gancyclovir.  $\beta$ -Galactosidase phenotype of the  $\text{Gls}^{\text{R}}$  clones was determined by X-Gal histochemical staining.

In the control series transfected with pCMV(I-SceI-),  $\text{Gls}^{\text{R}}$  resistant clones were found at a low frequency (2 clones for  $3 \times 10^{-6}$  treated cells) and the two were  $\beta\text{-Gal}^+$ . In the experimental series transfected with pCMV(I-SceI+), expression of the I-Sce I gene increased the frequency of  $\text{Gls}^{\text{R}}$  clones 100 fold. These clones were either  $\beta\text{-Gal}^-$  (93%) or  $\beta\text{-Gal}^+$  (7%). Five  $\beta\text{-Gal}^-$  clones from the NIH3T3/G-MtkPL 1 and six from the NIH3T3/G-MtkPL 2 were analyzed by Southern blotting using *Pst* I (Fig. 26). In the parental DNA, *Pst* I endonuclease cuts twice in the *tk* gene of the provirus (Fig. 26a). The sizes of the two *PhleoLacZ* containing fragments are determined by the position of the *Pst* I sites in the flanking cellular DNA. In NIH3T3/G-MtkPL 1, these two *PhleoLacZ* fragments are 10 kbp long and in NIH3T3/G-MtkPL 2 they are 7 and 9 kbp long. The five  $\text{Gls}^{\text{R}}$   $\beta\text{-Gal}^-$  resistant clones from NIH3T3/G-MtkPL 1 and the six clones from the NIH3T3/G-MtkPL 2 all showed an absence of the *tk* gene and of the two *PhleoLacZ* sequences (Fig. 26b and c).

In the experimental series the number of  $\text{Gls}^{\text{R}}$   $\beta\text{-Gal}^+$  clones is increased about 10 fold by I-Sce I expression in comparison to the control series. These were not analyzed further.

In order to increase the number of  $\text{Gls}^{\text{R}}$   $\beta\text{-Gal}^+$  clones recovered, in a second set of experiments, the cells were grown in a medium containing both Gancyclovir and Phleomycin. Gancyclovir selects for cells that have lost *tk* activity and Phleomycin for

cells that maintained the *PhleoLacZ* gene. We transfected NIH3T3/G-MtkPLs 1 and 2 with pCMV(I-SceI+) or pCMV(I-SceI-) (Table 2).

**Table 2**

Number of Phleo and Gls resistant clones

I-Sce I expression	pCMV(I-SceI+)	pCMV(I-SceI-)
NIH3T3/G-MtkPL 1	74	2
NIH3T3/G-MtkPL 2	207	9

**TABLE 2:** Effect of I-Sce I expression on the intra-chromosomal recombination frequency.  $2 \times 10^6$  cells of NIH3T3/G-MtkPL 1 and  $9 \times 10^6$  cells of NIH3T3/G-MtkPL 2 were transfected with either pCMV(I-Sce I+) or pCMV(I-Sce I-). Cells were cultured in Phleomycin and gancyclovir containing medium.

In the control series, the frequency of recovery of Phleo<sup>R</sup> Gls<sup>R</sup> resistant clones was  $1 \times 10^{-6}$ . This result reflects cells that have spontaneously lost *tk* activity, while still maintaining the *PhleoLacZ* gene active. In the experimental series, this frequency was raised about 20 to 30 fold, in agreement with the first set of experiments (Table 1).

The molecular structure of the Phleo<sup>R</sup> $\beta$ -Gal<sup>+</sup>Gls<sup>R</sup> clones was analyzed by Southern blotting (Fig. 27). Four clones from NIH3T3/G-MtkPL I were analyzed, two from the experimental series and two from the control. Their DNA was digested with *Pst* I endonuclease. If an intra-chromosomal event had occurred, we expected a single *Pst* I fragment of 13.6 kbp (that is the sum of the three *Pst* I fragments of the parental DNA minus the I-Sce I fragment, see Fig. 27a). All four Phleo<sup>R</sup>Gls<sup>R</sup> resistant clones exhibited this

13.6 kbp *Pst* I fragment, suggesting a faithful intra-molecular recombination (Fig. 27b).

DNA from eight clones from NIH3T3/G-MtkPL 2 cells were analyzed by Southern blotting using *Bcl* I digestion (six from the experimental series and two from the control). *Bcl* I digestion of the parental DNA results in one 7.2 kbp fragment containing the proviral sequences and in two flanking fragments of 6 kbp and 9.2 kbp. An intra-chromosomal recombination should result in the loss of the 7.2 kbp fragment leaving the two other bands of 6 kbp and 9.2 kbp unchanged (Fig. 27a). The eight clones (2.7 to 2.16) showed the disappearance of the tk containing 7.2 kbp fragment indicative of an intra-chromosomal recombination between the two LTRs (Fig. 27c).

## DISCUSSION

The results presented here demonstrate that the yeast I-Sce I endonuclease induces chromosomal recombination in mammalian cells. This strongly suggests that I-Sce I is able to cut in vivo a chromosome at a predetermined target.

Double-strand breaks in genomic sequences of various species stimulate recombination (21B, 19B). In the diploid yeast, a chromosomal DSB can lead to the use of the homo-allelic locus as a repair matrix. This results in a gene conversion event, the locus then becoming homozygous (30B). The chromosomal DSBs can also be repaired by using homologous sequences of an ectopic locus as matrix (32B). This result is observed at a significant level as a consequence of a DSB gap repair mechanism. If the DSB occurs between two direct-repeated chromosomal sequences, the mechanism

of recombination uses the single strand annealing (SSA) pathway (11B, 10B). The SSA pathway involves three steps: 1) an exonucleolysis initiated at the point of the break leaving 3' protruding single-strand DNAs; 2) a pairing of the two single strand DNAs by their homologous sequences, 3) a repair of the DNA by repairs complexes and mutator genes which resolve the non-homologous sequences (33B). A special case concerns the haploid yeast for which it has been showed that DSBs induced by HO or I-Sce I endonucleases in a chromosome leads to the repair of the break by end joining (34B). This occurs, but at a low efficiency (30B, 35B).

Our results show that the presence of two I-Sce I sites in a proviral target and the expression of the I-Sce I endonuclease lead to an increase in the deletion of a thymidine kinase gene at a frequency at least 100 fold greater than that occurring spontaneously. Two types of *tk* deleted clones arise from I-Sce I mediated recombination: clones that have kept (7%) and clones that have lost (93%) the *PhleoLacZ* sequences.

The generation of *tk*<sup>-</sup>*PhleoLacZ*<sup>+</sup> cells is probably the consequence of intra-chromosomal recombination. Studies have shown that in a recombinant provirus with an I-Sce I recognition site in the LTRs, the I-Sce I endonuclease leads in 20% of the cases to the cleavage of only one proviral I-Sce I site and in 80% to the cleavage of the two proviral I-Sce I sites. If only one of the two I-Sce I sites is cut by the endonuclease, an intra-chromosomal recombination can occur by the SSA pathway. If the two I-Sce I sites are cut, the *tk*<sup>-</sup>*PhleoLacC*<sup>+</sup> cells can be generated by end joining, allowing intra-chromosomal recombination

(see Figure 1). Although, in the diploid yeast, this pathway is not favorable (the break is repaired using homologous chromosomal sequences) (2B), it remains possible that this pathway is used in mammalian cells.

The generation of *tk<sup>-</sup>/PhleoLacZ<sup>-</sup>* cells is probably a consequence of either a homo-allelic and/or an ectopic gene conversion event (36B). Isolation and detailed molecular analysis of the proviral integration sites will provide information on the relative frequency of each of these events for the resolution of chromosomal DSBs by the cell. This quantitative information is important as, in mammalian cells, the high redundancy of genomic sequences raises the possibility of a repair of DSBs by ectopic homologous sequences. Ectopic recombination for repair of DSBs may be involved in genome shaping and diversity in evolution [29].

The ability to digest specifically a chromosome at a predetermined genomic location has several potential applications for genome manipulation.

The protocol of gene replacement described herein can be varied as follows:

#### Variety of donor vectors

Size and sequence of flanking regions of I-Sce - I site in the donor plasmid (done with 300 pb left and 2.5 kb right): Different constructions exist with various size of flanking regions up to a total of 11 kb left and right from I-Sce I site. The sequences depend from the construction (LTR, gene). Any sequence comprising between 3 00 bp to 11 kb can be used.

- Inserts (neo, phleo, phleo-LacZ and Pytk-neo have been constructed). Antibiotic resistance: neomycin, phleomycin;

00270 012700



reporter gene (LacZ); HSV1 thymidine kinase gene: sensitivity to gancyclovir. It is impossible to insert any kind of gene sequence up to 10 kb or to replace it. The gene can be expressed under an inducible or constitutive promoter of the retrovirus, or by gene trap and homologous recombination (i.e. Insulin, Hbs, ILs and various proteins).

Various methods can be used to express the enzyme I-Sce I: transient transfection (plasmid) or direct injection of protein (in embryo nucleus); stable transfection (various promoters like: CMV, RSV and MoMuLV); defective recombinant retroviruses (integration of ORF in chromosome under MoMuLV promoter); and episomes.

Variation of host range to integrate I-Sce I site:

Recombinant retroviruses carrying I-Sce I site (i.e. pG-MPL, pG-MtkPL, pG-Mtk $\Delta$ PAPL) may be produced in various packaging cell lines (amphotropic or xenotropic).

#### Construction of stable cell lines expressing I-Sce I and cell protection against retroviral infection

Stable cell line expressing I-Sce I are protected against infection by a retroviral vector containing I-Sce I site (i.e. NIH 3T3 cell line producing I-Sce I endonuclease under the control of the CMV promoter is resistant to infection by a pG-MPL or pGMtkPL or I-Sce I under MoMuLV promoter in  $\psi$  2 cells).

#### Construction of cell lines and transgenic animals containing the I-Sce I site

Insertion of the I-Sce I site is carried out by a classical gene replacement at the desired locus and at the appropriate position. It is then possible to screen the expression of different genes at the same location in the cell (insertion of the

002270 1692450

donor gene at the artificially inserted I-Sce I site) or in a transgenic animal. The effect of multiple drugs, ligands, medical protein, etc., can be tested in a tissue specific manner. The gene will consistently be inserted at the same location in the chromosome.

For "Unprepared" mouse cells, and all eucaryotic cells, a one step gene replacement/integration procedure is carried out as follows:

- Vectors (various donor plasmids) with I-Sce I site: one site within the gene (or flanking) or two sites flanking the donor gene.

- Method to express the enzyme

Transient expression: ORF on the same plasmid or another (cotransfection).

Specific details regarding the methods used are described above. The following additional details allow the construction of the following:

a cell line able to produce high titer of a variety of infective retroviral particles;

plasmid containing a defective retrovirus with I-Sce I sites, reporter-selector gene, active LTRs and other essential retroviral sequences; a plasmid containing sequences homologous to flanking regions of I-Sce I sites in above engineered retrovirus and containing a multiple cloning site; and a vector allowing expression of I-Sce I endonuclease and adapted to the specific applications.

Mouse fibroblast  $\psi$ 2 cell line was used to produce ectopic defective recombinant retroviral vectors containing I-Sce I sites.

0049007-012700

Cell lines producing plasmids as pG-MPL, pG-MtkPL, PG-Mtk $\Delta$ PA<sup>PL</sup> are also available. In addition, any cells, like mouse amphotropic cells lines (such as PA12) or xenotropic cells lines, that produce high titer infectious particles can be used for the production of recombinant retroviruses carrying I-Sce I site (i.e., pG-MPL, pG-MtkPL, pG-Mtk $\Delta$ PA<sup>PL</sup>) in various packaging cell lines (amphotropic, ectropic or xenotropic).

A variety of plasmids containing I-Sce I can be used in retroviral construction, including pG-MPL, pG-MtkPL, and pG-Mtk $\Delta$ PA<sup>PL</sup>. Others kind of plasmid vector can be constructed containing various promoters, genes, polyA site, and I-Sce I site. A variety of plasmid containing sequences homologs to flanking regions of I-Sce I can be constructed. The size and sequence of flanking regions of I-Sce I site in the donor plasmid are prepared such that 300 kb are to the left and 2.5 kb are to the right). Other constructions can be used with various sizes of flanking regions of up to about 11 kb to the left and right of the I-Sce I recognition site.

Inserts containing neomycin, phleomycin and phleo-LacZ have been constructed. Other sequences can be inserted such as drug resistance or reporter genes, including LacZ, HSV1 or thymidine kinase gene (sensibility to gancyclovir), insulin, CFTR, IL2 and various proteins. It is normally possible to insert any kind of sequence up to 12 kb, wherein the size depends on the virus capacity of encapsidation). The gene can be expressed under inducible or constitutive promoter of the retrovirus, or by gene trap after homologous recombination.

09492697 012700

A variety of plasmids containing I-Sce I producing the endonuclease can be constructed. Expression vectors such as pCMVI-SceI(+) or similar constructs containing the ORF, can be introduced in cells by transient transfection, electroporation or lipofection. The protein can also be introduced directly into the cell by injection of liposomes.

Variety of cells lines with integrated I-Sce I sites can be produced. Preferably, insertion of the retrovirus (proviral integration) induce duplication of LTR containing the I-Sce I site. The cell will be hemizygote for the site. Appropriate cell lines include:

1. Mouse Fibroblastic cell line, NIH 3T3 with 1 to 14 proviral integration of G-MPL. Multiple (more than 30) clones were recovered. The presence of and the multiplicity of the different genomic integrations (uncharacterized) were verified by molecular analysis.
2. Mouse Fibroblastic cell line, NIH 3T3 with 1 copy of G-MtkPL integrated in the genome. 4 clones were covered.
3. Mouse Embryonal Carcinoma cell line, PCC7-S with 1 to 4 copies of G-MPL proviral integration in the genome. 14 clones were covered.
4. Mouse Embryonal Carcinoma cell line, PCC4 with 1 copy of G-MtkPL integrated in the genome.
5. Mouse Embryonic Stem cell line D3 with 1 to 4 copies of G-MPL at a variety of genomic localisation (uncharacterized). 4 clones were recovered.

Construction of other cell lines and transgenic animals containing the I-Sce I site can be done by insertion of the

I-Sce I site by a classical gene replacement at the desired locus and at the appropriate position. Any kind of animal or plant cell lines could *a priori* be used to integrate I-Sce I sites at a variety of genomic localisation with cell lines adapted. The invention can be used as follows:

1. Site specific gene insertion

The methods allow the production of an unlimited number of cell lines in which various genes or mutants of a given gene can be inserted at the predetermined location defined by the previous integration of the I-Sce I site. Such cell lines are thus useful for screening procedures, for phenotypes, ligands, drugs and for reproducible expression at a very high level of recombinant retroviral vectors if the cell line is a transcomplementing cell line for retrovirus production.

Above mouse cells or equivalents from other vertebrates, including man, can be used. Any plant cells that can be maintained in culture can also be used independently of whether they have ability to regenerate or not, or whether or not they have given rise to fertile plants. The methods can also be used with transgenic animals.

2. Site specific gene expression

Similar cell lines can also be used to produce proteins, metabolites or other compounds of biological or biotechnological interest using a transgene, a variety of promoters, regulators and/or structural genes. The gene will be always inserted at the same localisation in the chromosome. In transgenic animals, it makes possible to test the effect of multiple drugs, ligands, or medical proteins in a tissue-specific manner.

3. Insertion of the I-Sce I recognition site in the CFTR locus using homologous sequences flanking the CFTR gene in the genomic DNA. The I-Sce I site can be inserted by spontaneous gene replacement by double-crossing over (Le Mouellic et al. PNAS, 1990, Vol. 87, 4712-4716).

4. Biomedical applications

A. In gene therapy, cells from a patient can be infected with a I-Sce I containing retrovirus, screened for integration of the defective retrovirus and then co-transformed with the I-Sce I producing vector and the donor sequence.

Examples of appropriate cells include hematopoietic tissue, hepatocytes, skin cells, endothelial cells of blood vessels or any stem cells.

I-Sce I containing retroviruses include pG-MPL, pG-MtkPL or any kind of retroviral vector containing at least one I-Sce I site.

I-Sce I producing vectors include pCMVI-Sce I(+) or any plasmid allowing transient expression of I-Sce I endonuclease.

Donor sequences include (a) Genomic sequences containing the complete IL2 gene; (b) Genomic sequences containing the pre-ProInsulin gene; (c) A large fragment of vertebrate, including human, genomic sequence containing *cis*-acting elements for gene expression. Modified cells are then reintroduced into the patient according to established protocols for gene therapy.

B. Insertion of a promoter (i.e., CMV) with the I-Sce I site, in a stem cell (i.e., lymphoid). A gap repair molecule containing a linker (multicloning site) can be inserted between the CMV promoter and the downstream sequence. The insertion of a

gene (i.e., IL-2 gene), present in the donor plasmids, can be done efficiently by expression of the I-Sce I meganuclease (i.e., co-transfection with a I-Sce I meganuclease expression vector). The direct insertion of IL-2 gene under the CMV promoter lead to the direct selection of a stem cell over-expressing IL-2.

For constructing transgenic cell lines, a retroviral infection is used in presently available systems. Other method to introduce I-Sce I sites within genomes can be used, including micro-injection of DNA, Ca-Phosphate induced transfection, electroporation, lipofection, protoplast or cell fusion, and bacterial-cell conjugation.

Loss of heterozygosity is demonstrated as follows: The I-Sce I site is introduced in a locus (with or without foreign sequences), creating a heterozygous insertion in the cell. In the absence of repair DNA, the induced double-strand break will be extend by non-specific exonucleases, and the gap repaired by the intact sequence of the sister chromatide, thus the cell become homozygotic at this locus.

Specific examples of gene therapy include immunomodulation (i.e. changing range or expression of IL genes); replacement of defective genes; and excretion of proteins (i.e. expression of various secretory protein in organelles).

It is possible to activate a specific gene *in vivo* by I-Sce I induced recombination. The I-Sce I cleavage site is introduced between a duplication of a gene in tandem repeats, creating a loss of function. Expression of the endonuclease I-Sce I induces the cleavage between the two copies. The reparation by recombination is stimulated and results in a functional gene.

00452697 "012700"

Site-directed genetic macro-rearrangements of chromosomes in cell lines or in organisms.

Specific translocation of chromosomes or deletion can be induced by I-Sce I cleavage. Locus insertion can be obtained by integration of one at a specific location in the chromosome by "classical gene replacement." The cleavage of recognition sequence by I-Sce I endonuclease can be repaired by non-lethal translocations or by deletion followed by end-joining. A deletion of a fragment of chromosome could also be obtained by insertion of two or more I-Sce I sites in flanking regions of a locus (see figure 32). The cleavage can be repaired by recombination and results in deletion of the complete region between the two sites (see figure 32).

00499697-012700



### References

1. Bernstein, N., Pennell, N., Ottaway, C. A. and Shulman, M.J. 1992. Gene replacement with one-sided homologous recombination. Mol. Cell Biol. 12: 360-367.
2. Bonnerot, C., Legouy, E., Choulika, A. and Nicolas, J.-F. 1992. Capture of a cellular transcriptional unit by retrovirus: mode of provirus activation in embryonal carcinoma cells. J. Virol. 66: 4982-4991.
3. Bonnerot, C., and Nicolas, J.-F. 1993. Application of LacZ gene fusions to post-implantation development. In "Methods in Enzymology: Guide to techniques in mouse development". 451-469. Wassarman, P.M., DePamphilis, M.L.
4. Brenner, D.A., Smogocki, A. and Camerini-Otero, R.D. 1986. Double-strand gap repair results in homologous recombination in mouse L cells. Proc. Natl. Acad. Sci. USA. 83: 1762-1766.
5. Capecchi, M.R. 1989. Altering the genome by homologous recombination. Science. 244: 1288-1292.
6. Jacquier, A. and Dujon, B. 1985. An intron encoded protein is active in a gene conversion process that spreads an intron into a mitochondrial gene. Cell. 41: 383-394
7. Jakob, H. and Nicolas, J.F. 1987. Mouse Tertocarcinoma Cells. In "Methods in Enzymology: Cell lines for genetic analysis". 66-81. Gottesman, M.H., ed., Academic Press.
8. Jessberger, R. and Berg, P. 1991. Repair of deletions and double-strand gaps by homologous recombination in a mammalian in vitro system. Mol. Cell Biol. 11: 445-457.

9. Kilby, N.J., Snaith, M.R. and Murray, J.A.H. 1993. Site-specific recombinases: tools for genome engineering. Reviews. 9: 413-421
10. Lin, F.L.M., Sperle, K. and Sternberg N. 1990. Repair of double-stranded DNA breaks by homologous DNA fragments during transfer of DNA into mouse L cells. Mol. Cell Biol. 10:113-119.
11. Lin, F.L.M., Sperle, K. and Sternberg N. 1990. Intermolecular recombination between DNAs introduced into mouse L cells is mediated by a nonconservative pathway that leads to crossover products. Mol. Cell Biol. 10: 103-112.
12. Lin, F.L.M., Sperle, K. and Sternberg N. 1990. Intermolecular recombination between DNAs introduced into mouse L cells is mediated by a nonconservative pathway that leads to crossover products. Mol. Cell. Biol. 10: 103-112.
13. Mann, R., Mulligan, R.C. and Baltimore, D. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell. 33: 153-160.
14. Mansour, S.L., Thomas K.R. and Capecchi, M.R. 1988. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable gene. Nature. 336:348-352.
15. Mulsant, P., Gatignol, A., Dolens, M. and Tiraby, G. 1988. Somat. Cell. Mol. Genet. 14: 243-252.
16. Nicolas, J. F. and Rubenstein, J. 1987. Retroviral vectors. Boston London Durban Singapore Sydney Toronto Wellington, Butterworths.
17. Plessis, A., Perrin, A., Haber, J.E. and Dujon, B. 1992. Site specific recombination determined by I-Sce I, a mitochondrial

002370 25926460

group I intron-encoded endonuclease expressed in the yeast nucleus. Genetics 130:451-460

18. Sauer, B. and Henderson, N. 1988. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl. Acad. Sci. USA. 85: 5166-5170.

19. Seidman, M.M. 1987. Intermolecular homologous recombination between transfected sequences in mammalian cells is primarily nonconservative. Mol. Cell. Biol. 7: 3561-3565.

20. Smithies, O., Gregg, R.G., Boggs, S.S., Koralewski, M.A. and Kucherlapati, R.S. 1985. Insertion of DNA sequences into the human chromosomal B-globin locus by homologous recombination. Nature. 317: 230-234.

21. Szostak, J. W., Orr-Weaver, T.L. and Rothstein, R.J. 1983. The double-strand break repair model for recombination. Cell. 33: 25-35.

22. Thierry, A., Perrin, A., Boyer, J., Fairhead, C., Dujon, B., Frey, B. and Schmitz, G. 1991. Cleavage of yeast and bacteriophage T7 genomes at a single site using the rare cutter endonuclease I-Sce I. Nucleic Acids Res. 19: 189-90

23. Tybulewicz, V.L. J., Crawford, C.E., Jackson, P.K., Bronson, R.T. and Mulligan, R.C. 1991. Neonatal Lethality and Lymphopenia in Mice with a Homozygous Disruption of the c-abl Proto-Oncogene. Cell 65: 1153-1163

24. Varmus, H. and Brown, P. 1989. Retroviruses

25. Weiss, R., Teich, N., Varmus, H. and Coffin, J. 1985. RNA tumor viruses. Molecular Biology of tumor viruses. Second Edition. 2) Supplements and appendixes. Cold Spring Harbor Laboratory. 1-1222.

0949697 032700

26. Weiss, R., Teich, N., Varmus, H. and Coffin, J. 1985. RNA tumor viruses. Molecular Biology of tumor viruses. Second Edition. 2) Supplements and appendixes. Cold Spring Harbor Laboratory. 1-1222.
27. Phillips J. and Morgan W. 1994. Illegitimate recombination induced by DNA double-strand breaks in mammalian chromosomes. Molecular and Cellular Biology 14:5794-5803.
28. Dujon B. 1989. Group I introns are mobile genetic elements: facts and mechanistic speculations-a review. Gene 82:91-114.
29. Colleaux L., D'Aurio L., Galibert F. and Dujon B. 1988. Recognition and cleavage site of the intron-encoded omega transposase. Proc Natl Acad Sci USA 85:6022-6.
30. Fairchild C. and Dujon B. Consequences of unique double-stranded breaks in yeast chromosomes: death or homozygosis. Molecular general genetics 240:170-180.
31. Pfeiffer P., Thode S., Hancke J. and Vielmetter W. 1994. Mechanism of overlap information in nonhomologous DNA end joining. Molecular and Cellular Biology 14:888-895.
32. Mezard C. and Nicholas A. 1994. Homologous, homeologous, and illegitimate repair of double-strand breaks during transformation of a wild-type strain and a rad52 Mutant strain of *Saccharomyces cerevisiae*. Molecular and Cellular Biology 14:1278-1292.
33. Feaver W.J., Svejstrup J.Q., Bradwell L., Bradwell A.J., Buratowski S., Gulyas K., Donahue T.F., Friedberg E.C. and Kornberg R.D. 1993. Dual Roles of a Multiprotein Complex from *S. cerevisiae* in transcription and DNA Repair. Cell 75:1379-1387.

34. Kramer K., Brock J., Bloom K., Moore K. and Haber J. 1994. Two different types of double-strand breaks in *Saccharomyces cerevisiae* are repaired by similar RAD52 independent, nonhomologous recombination events. *Molecular and Cellular Biology* 14:1293-1301.
35. Weiffenbach B. and Haber J. 1981. Homothallelic mating type switching generates lethal chromosome breaks in rad52 strains of *Saccharomyces cerevisiae*. *Molecular and Cellular Biology* 1:522-534.
36. Nassif N., Penney J., Pal S., Engels W. and Gloor G. 1994. Efficient copying of nonhomologous sequences from ectopic sites via P-element-induced gap repair. *Molecular and cellular biology* 14:1643-1625.
37. Charlesworth B., Sniegowski P. and Stephan W. 1994. The evolutionary dynamics of repetitive DNA in eucaryotes. *Nature* 371:215-220.

WE CLAIM:

1. A method of inducing at least one site-directed double-strand break in DNA of a cell, said method comprising

(a) providing cells containing double-stranded DNA, wherein said DNA comprises at least one I-Sce I restriction site;

(b) transfecting said cells with at least a plasmid comprising DNA encoding the I-Sce I meganuclease; and

(c) selecting cells in which at least one double-strand break has been induced.

2. The method of claim 1, wherein said cell is selected from the group consisting of a mammalian cell, a yeast cell, and a plant cell.

3. The method of claim 2, wherein said cell is an NIH3T3 cell containing the G-MtkPL virus.

4. The method of claim 1, wherein said plasmid is pCMV(I-Sce I+).

5. A method of inducing homologous recombination between chromosomal DNA of a cell and exogenous DNA added to said cell, said method comprising

(a) providing cells containing chromosomal DNA, wherein said DNA comprises at least one I-Sce I restriction site;

(b) transfecting said cells with a plasmid comprising exogenous DNA, and with a plasmid comprising DNA encoding the I-Sce I meganuclease; and

(c) selecting cells in which said exogenous DNA is inserted into said chromosomal DNA.

09493697 "012700

6. The method of claim 5, wherein said cell is selected from the group consisting of a mammalian cell, a yeast cell, and a plant cell.

7. The method of claim 6, said cell is an NIH3T3 cell containing the G-MtkPL virus.

8. The method of claim 5, wherein said plasmid is pCMV(I-Sce I+).

9. A method of inducing homologous recombination between chromosomal DNA of a cell and exogenous DNA added to said cell, said method comprising

- (a) providing cells comprising chromosomal DNA;
- (b) inserting at least one I-Sce I restriction site in said chromosomal DNA;
- (c) transfecting said cells with a first plasmid comprising exogenous DNA, and with a second plasmid comprising DNA encoding the I-Sce I meganuclease; and
- (d) selecting cells in which said exogenous DNA is inserted into said chromosomal DNA.

10. The method of claim 9, wherein said cell is selected from the group consisting of a mammalian cell, a yeast cell, and a plant cell.

11. The method of claim 9, wherein said first plasmid is pCMV(I-Sce I+).

12. The method of claim 9, wherein said second plasmid is pVRneo.

13. A method of inducing at least one site-directed break in DNA of a cell and inserting DNA encoding a polypeptide, said method comprising,

(a) providing cells containing double-stranded DNA, wherein said cells are capable of being transformed by a DNA comprising a I-Sce I restriction site and DNA encoding said polypeptide;

(b) adding *Sce* I enzyme or transforming said cell with DNA encoding *Sce* I enzyme;

(c) transfecting said cells with said DNA encoding said polypeptide or with a vector containing said DNA; and

(d) selecting cells transfected with said DNA or said vector, wherein said cells express said polypeptide.

14. A recombinant eukaryotic cell transformed by the method of any one of claims 1 and 13.

15. A transgenic animal comprising a cell transformed by the method of any one of claims 1 and 13.

16. A method of expressing a polypeptide in a transgenic animal, said method comprising transforming embryonic stem cells with a DNA comprising a I-Sce I restriction site and DNA encoding said polypeptide, and detecting expression of said polypeptide in a transgenic animal resulting from said transformed embryonic stem cells.

17. A recombinant stem cell expressing a polypeptide, wherein said stem cell is transformed by a DNA comprising a I-Sce I restriction site and DNA encoding said polypeptide by

(a) adding *Sce* I enzyme to said cell or transforming said cell with a vector containing the gene coding for *Sce* I enzyme;

(b) transfecting said cells with said DNA encoding said polypeptide; and

(c) selecting cells transfected with said DNA, wherein said cells express said polypeptide.

09492697 012700



18. A recombinant eukaryotic cell as claimed in any one of claims 4 and 7 wherein said polypeptide is a foreign antigen to the cell.

19. The recombinant eukaryotic cell as claimed in claim 14 wherein cell is a mammalian cell line.

20. The recombinant eukaryotic cell as claimed in claim 14 wherein cell is a yeast.

21. A method of inducing at least one site-directed break in DNA of cells and inserting DNA encoding a polypeptide, wherein said cells express at least one protein product, said method comprising,

(a) providing cells containing double-stranded DNA, wherein said cells are capable of being transformed by a DNA comprising a I-Sce I restriction site and DNA encoding said polypeptide;

(b) adding Sce I enzyme to said cells or transforming said cells with DNA encoding Sce I enzyme;

(c) transfecting said cells with said DNA encoding said polypeptide or with a vector containing said DNA; and

(d) selecting cells transfected with said DNA or said vector, wherein said cells express said polypeptide and do not express said protein product.

22. A recombinant cell transformed by the method of claim 21.

002210 05926460

ABSTRACT

An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.

00493697 012700



FIGURE 1

The Universal Code Equivalent of  
the Mitochondrial 1-Sce I Gene.

AAAAAATAAAATCAT ATG AAA AAT ATT AAA AAA AAT CAA GTA ATG AAT CTC CGT CCT AAT TCT  
 M K N I K K N Q V M N L Q P N S  
 AAA TTA TTA AAA GAA TAT AAA TCA CAA TTA ATT GAA TTA AAT ATT GAA CAA TTT GAA TTA  
 K L L K E Y K S Q L I E L N I E Q F E A  
 GGT ATT GGT TTA ATT TTA GGA GAT GCT TAT ATT CGT AGT CGT GAT GAA GGT AAA ACT TAT  
 G I G L I L G D A Y I R S R O E Q K T Y  
 TGT ATG CAA TTT CAC TGC AAA AAT AAG GCA TAC ATG GAT CAT GTA TGT TTA TTA TAT GAT  
 C H Q F E W K N K A Y M O H V C L L Y D  
 CAA TGG GTA TTA TCA CCT CCT CAT AAA AAA GAA AGA GTT AAT CAT TTA GGT AAT TTA GTA  
 Q W V L S P P H K K E R V N H L Q N L V  
 ATT ACC TGG GGA GCT CAA ACT TTT AAA CAT CAA GCT TTT AAT AAA TTA GCT AAC TTA TTT  
 I T W G A Q T F K H Q A F N K L A N L F  
 ATT GTA AAT AAT AAA AAA CTT ATT CCT AAT AAT TTA GTT GAA AAT TAT TTA ACA CCT ATG  
 I V N N K K L I P N N L V E N Y L T P H  
 AGT CTG GCA TAT TGG TTT ATG GAT GAT GGA GGT AAA TGG GAT TAT AAT AAA AAT TCT CTT  
 S L A Y W F M D D Q G K W D Y N K N S L  
 AAT AAA AGT ATT GTA TTA AAT ACA CAA AGT TTT ACT TTT GAA GAA GTA GAA TAT TTA CTT  
 M K S I V L N T Q S F T F E E V C Y L V  
 AAA GGT TTA AGA AAT AAA TTT CAA TTA AAT TGT TAT GTT AAA ATT AAT AAA AAT AAA CCA  
 K G L R N K P Q L N C Y V K I N K N K P  
 ATT ATT TAT ATT GAT TCT ATG AGT TAT CTG ATT TTT TAT AAT TTA ATT AAA CCT TAT TTA  
 I I Y I D S H S Y L I F Y N I I K P Y L  
 ATT CCT CAA ATG ATG TAT AAA CTG CCT AAT ACT ATT TCA TCC GAA ACT TTT TTA AAA TAA  
 I P Q H H Y K L P N T I S S E T F L K

00493697-012700

FIGURE 2


The synthetic I-Sce I gene

Bam HI

CCGGATCCATG CAT ATG AAA AAC ATC AAA AAA AAC CAG GTA ATG AAC CTG GGT CCG AAC TCT  
M H M K N I K K N Q V M N L G P N S  
AAA CTG CTG AAA GAA TAC AAA TCC CAG CTG ATC GAA CTG AAC ATC GAA CAG TTC GAA GCA  
K L L K E Y K S Q L I E L N I E G F E A  
1. GGT ATC GGT CTG ATC CTG GGT GAT GGT TAC ATC CGT TCT CGT GAT GAA GGT AAA ACC TAC  
G I G L I L G D A Y I R S R D E G K T Y  
TGT ATG CAG TTC GAG TGG AAA AAC AAA GCA TAC ATG GAC CAC GTA TGT CTG CTG TAC CAT  
C M Q F E W K N K A Y M D H V C L L Y D  
CAG TGG GTA CTG TCC CCG CCG CAC AAA AAA GAA CGT GTT AAC CAC CTG GGT AAC CTG GTA  
Q W V L S P P H K K E R V N H L G N L V  
ATC ACC TGG GGC GGC CAG ACT TTC AAA CAC CAA GCT TTC AAC AAA CTG GGT AAC CTG TTC  
I T W G A Q T F K H Q A F N K L A N L F  
ATC GTT AAC AAC AAA AAA ACC ATC CCG AAC AAC CTG GTT GAA AAC TAC CTG ACC CCG ATG  
I V N N K K T I P N N L V E N Y L T P M  
2. TCT CTG GCA TAC TGG TTC ATG GAT GAT GGT GGT AAA TGG GAT TAC AAC AAA AAC TCT ACC  
S L A Y W F M D D S G K W D Y N K N S T  
AAC AAA TCG ATC GTA CTG AAC ACC CAG TCT TTC ACT TTC GAA GAA GTA GAA TAC CTG GTT  
N K S I V L N T Q S F T F E E V E Y L V  
AAC GGT CTG CGT AAC AAA TTC CAA CTG AAC TGT TAC GTA AAA ATC AAC AAA AAC AAA CCG  
K G L R N K F Q L N C Y V K I N K N K P  
ATC ATC TAC ATC GAT TCT ATG TCT TAC CTG ATC TTC TAC AAC CTG ATC AAA CCG TAC CTG  
I I Y I D S M S Y L I F Y N L I K P Y L  
ATC CCG CAG ATG ATG TAC AAA CTG CCG AAC ACT ATC TCC TCC GAA ACT TTC CTG AAA TAA  
I P Q M M Y K L P N T I S S E T F L K  
TAAGTCCACTGCAGGATCCGGTAAGTAAGTAA  
Sall PstI BamHI

1 and 2: These amino acids are absolutely necessary to produce catalytic activity. Other substitutions are possible, such as deletions of the 10 first amino acids.

FIGURE 3



[illegible]

I-SceI coding sequence of pSCM525 - Note the two amino acid N-terminal extension as compared to genuine version of the gene.

## VARIATIONS AROUND THE I-Sce I SEQUENCE

[illegible]

Positions that can be changed without affecting enzyme activity (demonstrated)

positions -1 and -3 are not natural. The two amino acids are added due to cloning strategies

positions 1 to 10: can be deleted

position\_36: G is tolerated

position 40: M or Y are tolerated

position 41: S or N are tolerated

position 43: A is tolerated

position 44: Y or N are tolerated

position 91: A is tolerated

positions 153 and 156: L are tolerated

position 225: A and S are tolerated

Chemicals that affect enzyme activity (demonstrated)

position 13: L to 8

position SS: 1 to 8 or N

position 39: G to D or B

position 40: L to Q

position 42: L to R

position 44: D to E, G or H

position 45: A to E or D

```

position 46: Y to D

```

position 47: I to R or N

position 60: L to S

position 144:D to E

position 145: D to E

position 14GG to E

FIGURE 6

Group I Intron Encoded Endonucleases and Related Endonucleases

Endonuclease	Recognition Sequence	Cleavage Site	Intron site
Two Dodecapatide Family (for 4 bp cutters)	I-Sce I ( <i>Saccharomyces mitochondria</i> )	CGCTAGGGGATAACAGGGGTAATATACCG GGGATGGGCTATTTCTCCCTATATACCG	▼
	I-Sce IV ( <i>Saccharomyces mitochondria</i> )	TTCTCATCAGGTAAGCTCTAATCCAGCG AAGAGTACCTAATCCAGAGATCAGGTAACCG	▼
	I-Sce II ( <i>Saccharomyces mitochondria</i> )	CTTTGGTCTACCGAGAGGTAATATATCTT GAAACGAGTAACTTCTCTATATATATAA	▼
	I-Ceu I ( <i>Chlamydomonas chloroplast</i> )	TACGGGTCTCTAAAGCTAGCGGAATTTCA ATTGCCAGGATTCCTATCGCTTTTAACTT	▼
	I-Hpo I ( <i>Physarum nucleus</i> )	TGACCTCTCTAAAGCTAGCGGAATTTCA ACTGAGAGGATTCCTATCGCTTTTAACTT	▼
	I-Sce III ( <i>Saccharomyces mitochondria</i> )	CGAGGTTTTTCTAAGTATTTTATTTACCG CCTCCGAAAUCAATTGATATAAATAATGG	▼
	I-Ceu I ( <i>Chlamydomonas chloroplast</i> )	GGGTTCAAAACGTTCTGTCAGACAGTTT CCCAGTTTTTTCAGCACCTCTCTCTATAA	▼
	Endo Sce I (RF3) ( <i>Saccharomyces mitochondria</i> ) (Non isozyme)	GATGCTGTAGGCTATAGGCTTTGGTTAT CTAGGACATTCGCTATCGGGAACCAATA	▼
	HO ( <i>Saccharomyces nucleus</i> ) (Non isozyme)	CTTTCGGGCAACAGTATATAATTTTATAA CAAAAGGCTTTCTCATATTTTAAATATTT	▼
	I-Cem I ( <i>Chlamydomonas mitochondria</i> ) (Putative endonuclease)	ACCATGGGGGTCAAATGTCTTTCTGGG TGGTACCCCGATTTTACAGAAAGACCC	▼
	I-Pan I ( <i>Podospira mitochondria</i> ) (Putative endonuclease)	GTCCTCTAAAGCTATATTTTCTCTCTT CACCCAGCTTACTATATAATAATGGAAA	▼
Other Structural Families	(Bacteriophage T4)		▼
	I-Tev I	GAACGCTCTCAGTATGTTTTCTTGGGCTCTACCGTTTAAAT GTTTCCGAGTCTATCTAUAAGAAACCCAGATGGCAATTA	▼
	I-Tev II	CAAGCTTATGATATGAAGTGAACACGTTTATTT GTTCTGAATACTCATACCTTCACTTGTGCAATTA	▼
	I-Tev III	GCTATTCGTTTCTTATGATATCTTTTGGCTCTACCGTTTAAAT CAATTAAGCAAAATTCATAGAAAGCCACATGGCAATTT	▼



FIGURE 7

EXPRESSION VECTORS






FIGURE 8



00707 28926450

FIGURE 9



00492697 043700

PAF 100 - RESTRICTION MAP

SauIA I  
Hho I  
Xpn II

Sbf I  
Nci I  
Msp I  
Epa II  
Dsa V  
BstK I  
Sma I  
SacI  
ScrF I  
Not I  
Uta V

Rsa I Dpn I  
Nla IV Nla IV  
Kpn I BclII

BamHI Xba I Kpn I Alw I  
PvuII PstI Sal I  
Ava I Sfi I HincII  
Taq I Msp7524 I AflIII Ava I PstI RseI  
AluI MspI RsaI Asp718 ALW I AccI RraI

EcoRI Xba I BamHI BanHI HindII  
Msp7524 I AflIII Ava I PstI RseI

I-SceI site

EcoRV

CCAGCTTCGAATTGCGATCCTGTACAGCTGCCATCCCCGGCATGCCTOCAGTCAGCCGACTGATAACAGCAAAACAGAT 2220  
GGTTCCGAGCTTAAGCTTAGTGAGATCTCCAGCCATCCCCCTAGGACCTCACCTGCGATCCCTATTGTCCAAGAATCTTA

| | . || | | . || | | | | | | | |  
2244 2255 2262 2271 2279 2286 2296 2318  
2247 2255 2266 2275 2284 2299  
2249 2261 2271 2279 2289  
2255 2265 2275 2284  
2255 2265 2276 2289  
2256 2265 2275 2290  
2263 2275  
2265 2272 2280  
2271 2279  
2271 2279  
2279 2290  
  
2275  
2275  
2275  
2275  
2275  
2276  
2276  
2276  
2276  
2276  
  
2280  
2280  
2280



[illegible]


FIGURE 11

Names : pT $\Sigma$ m  $\omega$   
pTKm  $\omega$   
pTTc  $\omega$






Construction : pGP 704 from De Lorenzo, with transposase gene and insertion of the linker [I-SceI] in NotI unique site

FIGURE 12



Construction : pD 123 , from J. D. Boeke  
with insertion of a linker [ I-SceI - NotI ] in BamHI

FIGURE 13








FIGURE 15







FIGURE 16




FIGURE 17





FIGURE 18



002270 459246

FIGURE 19





Figure 20




Figure 21








Figure 22





B.



LTR
PhleoLacZ
← tk thymidine kinase

002370 25925460

Figure 23



□ LTR ■ *PhleoLacZ* ■ *neo* ▨ *PolyA* — Genomic DNA ← *tk* thymidine kinase

Figure 24








Figure 25

a. Chromosomal DNA containing provirus

Phenotypes



b. Intra-chromosomal recombinations events



c. Inter-chromosomal recombination event







Figure 26

a. Parental DNA, G-MtkPL



b.



c.






Figure 27


a. 1. Parental DNA, G-MtkPL




2. Intra-molecular recombination event



b.




c.




# LOSS OF HETEROZYGOSITY

- 1 OCT 1991


Integration of artificial site or presence of specific site



Expression of I-Sce I and specific cleavage



Repair of the DSB with the other chromatid




004336 04300


Figure 29

CONDITIONNAL ACTIVATION (Tandem repeat)


Integration of artificial site between tandem repeats



Expression of I-Sce I and specific cleavage




Repair of the DSB by single strand annealing






## ONE STEP REARRANGEMENT

Integration of artificial site or presence of specific site



Expression of I-Sce I enzyme  
and  
specific cleavage of the donor plasmid




Recombination between the chromosome and plasmid




# DUPLICATION OF A LOCUS


## 1 insertion of I-Sce I site by classical gene replacement



## 2 Specific cleavage by I-Sce I enzyme and repair of the break by homologous sequences




## 3 Duplication of the totality of the locus




# DELETION OF A LOCUS

## 1 Insertion of two I-Sce I sites flanking the locus




## 2 Expression of the enzyme and cleavage



## 3 Recombination between the two ends




## 4 deletion of the locus



00270 2592460

Figure 33



**DECLARATION AND POWER OF ATTORNEY**

As below named inventors, we hereby declare that: our residence, post office address and citizenship are as stated below next to our names; that we believe we are the original, first and sole inventors (if only one name is listed below) or original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: NUCLEOTIDE SEQUENCE ENCODING THE ENZYME I-SCE I AND THE USES THEREOF, the specification of which is ☐ attached and/or ☒ was filed on November 7, 1994, as Application Serial No. 08/336,241

..... and amended on .....

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:


Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
---------	--------------------	----------------	---

We hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number	Date of Filing	Status (patented, pending, abandoned)
07/971,160	11/05/92	Pending
07/879,689	05/05/92	Abandoned

We hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Finnegan, Henderson, Farabow, Garrett and Dunner, Reg. No. 22,540; Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilly, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; and Thomas W. Winland, Reg. No. 27,605; Basil J. Lewris, Reg. No. 28,818; Robert J. Gaybrick, Reg. No. 27,890; Martin I. Fuchs, Reg. No. 28,508; Barry W. Graham, Reg. No. 29,924; Stephen J. Rosenman, Reg. No. 29,209; and Thomas H. Jenkins, Reg. No. 30,857; E. Robert Yoches, Reg. No. 30,120; Susan H. Griffen, Reg. No. 30,907; Richard B. Racine, 30,415; Robert E. Converse, Jr., Reg. No. 27,432; Christopher P. Foley, Reg. No. 31,354; Kenneth J. Meyers, Reg. No. 25,146; and Jane E.R. Potter, Reg. No. 33,332. Please address all correspondence to FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER, 1300 I Street, N.W., Suite 700, Washington, D.C. 20005, Telephone No. (202) 408-4000.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	INVENTOR'S SIGNATURE	DATE
Bernard DUJON		3 FEB 95
RESIDENCE	CITIZENSHIP	
91190 Gif Sur Yvette, FRANCE	French	
POST OFFICE ADDRESS		
6 rue de la Gruerie, 91190 Gif Sur Yvette, FRANCE		

: DATE

: 年 長 大

: CITIZENSHIP

: Lebanese

: INVENTOR'S SIGNATURE

: DATE

2

7 FEB 95

: CITZENSHP

: French

**: INVENTOR'S SIGNATURE**

: DATE

•

: 82-07-95

: CITIZENSHIP

: French

idem

: DATE

•

: CITIZENSHIP

: INVENTOR'S SIGNATURE

: DATE

---

: CITIZENSHIP

### POST OFFICE ADDRESS

Kategorie		Anzahl		Prozent	
Gruppe	Untergruppe	absolut	relativ	absolut	relativ
Gesamt	...	...	...	...	...
	...	...	...	...	...
	...	...	...	...	...
	...	...	...	...	...
Gruppe 1	...	...	...	...	...
	...	...	...	...	...
	...	...	...	...	...
	...	...	...	...	...
Gruppe 2	...	...	...	...	...
	...	...	...	...	...
	...	...	...	...	...
	...	...	...	...	...

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Choulika, Andre  
Perrin, Arnaud  
Dujon, Bernard  
Nicolas, Jean-Francois
- (ii) TITLE OF INVENTION: Nucleotide Sequence Encoding the Enzyme  
I-SCEI and the Uses Thereof
- (iii) NUMBER OF SEQUENCES: 52
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &  
Dunner
  - (B) STREET: 1300 I Street, N.W.
  - (C) CITY: Washington
  - (D) STATE: D.C.
  - (E) COUNTRY: USA
  - (F) ZIP: 20005-3315
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: Unassigned
  - (B) FILING DATE: 25-JAN-2000
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 09/244,130
  - (B) FILING DATE: 04-FEB-1999
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 09/119,024
  - (B) FILING DATE: 20-JUL-1998
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 08/336,241
  - (B) FILING DATE: 07-NOV-1994
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 07/971,160
  - (B) FILING DATE: 05-NOV-1992
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 07/879,689
  - (B) FILING DATE: 05-MAY-1992
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Meyers, Kenneth J.
  - (B) REGISTRATION NUMBER: 25,146
  - (C) REFERENCE/DOCKET NUMBER: 3495-0111-11

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 202-408-4000
- (B) TELEFAX: 202-408-4400

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 714 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGCATATGA AAAACATCAA AAAAAACCAG GTAATGAACC TCGGTCCGAA CTCTAAACTG 60  
CTGAAAGAAT ACAAATCCCA GCTGATCGAA CTGAACATCG AACAGTTCGA AGCAGGTATC 120  
GGTCTGATCC TGGGTGATGC TTACATCCGT TCTCGTGATG AAGGTAAAAC CTACTGTATG 180  
CAGTTCGAGT GGAAAAACAA AGCATACATG GACCACGTAT GTCTGCTGTA CGATCAGTGG 240  
GTACTGTCCC CGCCGCACAA AAAAGAACGT GTTAACCACC TGGGTAACCT GGTAATCACC 300  
TGGGGCGCCC AGACTTTCAA ACACCAAGCT TTCAACAAAC TGGCTAACCT GTTCATCGTT 360  
AACAACAAAA AAACCATCCC GAACAACCTG GTTGAAAACCT ACCTGACCCC GATGTCTCTG 420  
GCATACTGGT TCATGGATGA TGGTGGTAAA TGGGATTACA ACAAAAACCTC TACCAACAAA 480  
TCGATCGTAC TGAACACCCA GTCTTTCCTT TTCGAAGAAG TAGAATACCT GGTTAAGGGT 540  
CTGCGTAACA AATTCCAACCT GAACTGTTAC GTAAAAATCA ACAAAAACAA ACCGATCATC 600  
TACATCGATT CTATGTCTTA CCTGATCTTC TACAACCTGA TCAAACCGTA CCTGATCCCCG 660  
CAGATGATGT ACAAACCTGCC GAACACTATC TCCTCCGAAA CTTTCCTGAA ATAA 714

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 237 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met His Met Lys Asn Ile Lys Lys Asn Gln Val Met Asn Leu Gly Pro  
1 5 10 15

Asn Ser Lys Leu Leu Lys Glu Tyr Lys Ser Gln Leu Ile Glu Leu Asn







Asp	Gly	Gly	Lys	Trp	Asp	Tyr	Asn	Lys	Asn	Ser	Leu	Asn	Lys	Ser	Ile
145					150					155					160
Val	Leu	Asn	Thr	Gln	Ser	Phe	Thr	Phe	Glu	Glu	Val	Cys	Tyr	Leu	Val
				165					170					175	
Lys	Gly	Leu	Arg	Asn	Lys	Phe	Gln	Leu	Asn	Cys	Tyr	Val	Lys	Ile	Asn
			180					185					190		
Lys	Asn	Lys	Pro	Ile	Ile	Tyr	Ile	Asp	Ser	Met	Ser	Tyr	Leu	Ile	Phe
		195					200					205			
Tyr	Asn	Ile	Ile	Lys	Pro	Tyr	Leu	Ile	Pro	Gln	Met	Met	Tyr	Lys	Leu
	210					215					220				
Pro	Asn	Thr	Ile	Ser	Ser	Glu	Thr	Phe	Leu	Lys					
225					230					235					

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 754 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCGGATCCAT GCATATGAAA AACATCAAAA AAAACCAGGT AATGAACCTG GGTCCGAACT	60
CTAAACTGCT GAAAGAATAC AAATCCCAGC TGATCGAACT GAACATCGAA CAGTTCGAAG	120
CAGGTATCGG TCTGATCCTG GGTGATGCTT ACATCCGTTC TCGTGATGAA GGTA AACCT	180
ACTGTATGCA GTTCGAGTGG AAAAACAAAG CATA CATGGA CCACGTATGT CTGCTGTACG	240
ATCAGTGGGT ACTGTCCCCG CCGCACAAAA AACAACGTGT TAACCACCTG GGTAACCTGG	300
TAATCACCTG GGGCGCCCAG ACTTTCAAAC ACCAAGCTTT CAACAACTG GCTAACCTGT	360
TCATCGTTAA CAACAAAAAA ACCATCCCGA ACAACCTGGT TGAAAACTAC CTGACCCCGA	420
TGTCTCTGGC ATACTGGTTC ATGGATGATG GTGGTAAATG GGATTACAAC AAAA ACTCTA	480
CCAACAAATC GATCGTACTG AACACCCAGT CTTTCACTTT CGAAGAAGTA GAATACCTGG	540
TTAAGGGTCT GCGTAACAAA TTCCA ACTGA ACTGTTACGT AAAAATCAAC AAAAACA AAC	600
CGATCATCTA CATCGATTCT ATGTCTTACC TGATCTTCTA CAACCTGATC AAACCGTACC	660
TGATCCCGCA GATGATGTAC AA ACTGCCGA ACACTATCTC CTCCGAACT TTCCTGAAAT	720
AATAAGTCGA CTGCAGGATC CGGTAAGTAA GTAA	754

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 11 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AATGCTTTCC A

11

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 25 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GTTACGCTAG GGATAACAGG GTAAT

25

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 25 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CAATGCGATC CCTATTGTCC CATTA

25

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 1738 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG AGCGCACGAG GGAGCTTCCA	60
GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC GCCACCTCTG ACTTGAGCGT	120
CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA AAAACGCCAG CAACGCGGCC	180
TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA TGTTCTTTCC TCGGTTATCC	240
CCTGATTCTG TGGATAACCG TATTACCGCC TTTGAGTGAG CTGATACCGC TCGCCGCAGC	300
CGAACGACCG AGCGCAGCGA GTCAGTGAGC GAGGAAGCGG AAGAGCGCCC AATACGCAAA	360
CCGCCTCTCC CCGCGCGTTG GCCGATTCAT TAATGCAGCT GGCACGACAG GTTTCCCGAC	420
TGGAAAGCGG GCAGTGAGCG CAACGCAATT AATGTGAGTT AGCTCACTCA TTAGGCACCC	480
CAGGCTTTAC ACTTTATGCT TCCGGCTCGT ATGTTGTGTG GAATTGTGAG CGGATAACAA	540
TTTCACACAG GAAACAGCTA TGACCATGAT TACGAATTCT CATGTTTGAC AGCTTATCAT	600
CGATAAGCTT TAATGCGGTA GTTTATCACA GTTAAATTGC TAACGCAGTC AGGCACCGTG	660
TATGAAATCT AACAATGCGC TCATCGTCAT CCTCGGCACC GTCACCCTGG ATGCTGTAGG	720
CATAGGCTTG GTTATGCCGG TACTGCCGGG CCTCTTGCGG GATATCCGCC TGATGCGTGA	780
ACGTGACGGA CGTAACCACC GCGACATGTG TGTGCTGTTC CGCTGGGCAT GCCAGGACAA	840
CTTCTGGTCC GGTAACGTGC TGAGCCCGGC CAAGCTTACT CCCCATCCCC CTGTTGACAA	900
TTAATCATCG GCTCGTATAA TGTGTGGAAT TGTGAGCGGA TAACAATTTT ACACAGGAAA	960
CAGGATCCAT GCATATGAAA AACATCAAAA AAAACCAGGT AATGAACCTG GGTCCGAAC	1020
CTAAACTGCT GAAAGAATAC AAATCCCAGC TGATCGAACT GAACATCGAA CAGTTCGAAG	1080
CAGGTATCGG TCTGATCCTG GGTGATGCTT ACATCCGTTC TCGTGATGAA GGTAACCT	1140
ACTGTATGCA GTTCGAGTGG AAAAACAAG CATACATGGA CCACGTATGT CTGCTGTACG	1200
ATCAGTGGGT ACTGTCCCCG CCGCACAAAA AAGAACGTGT TAACCACCTG GGTAACCTGG	1260
TAATCACCTG GGGCGCCCAG ACTTTCAAAC ACCAAGCTTT CAACAACTG GCTAACCTGT	1320
TCATCGTTAA CAACAAAAAA ACCATCCCGA ACAACCTGGT TGAAAACTAC CTGACCCCGA	1380
TGTCTCTGGC ATACTGGTTC ATGGATGATG GTGGTAAATG GGATTACAAC AAAAATCTA	1440
CCAACAAATC GATCGTACTG AACACCCAGT CTTTCACTTT CGAAGAAGTA GAATACCTGG	1500
TTAAGGGTCT GCGTAACAAA TTCCAATGA ACTGTTACGT AAAAATCAAC AAAAACAAC	1560
CGATCATCTA CATCGATTCT ATGTCTTACC TGATCTTCTA CAACCTGATC AAACCGTACC	1620
TCATCCCCCA GATGATGTAC AAAGTGCCGA AACTATCTC CTCCGAACT TTCCTGAAAT	1680
AATAAGTCGA CCTGCAGCCC AAGCTTGGCA CTGGCCGTCG TTTTACAACG TCGTGACT	1738

(2) INFORMATION FOR SEQ ID NO:10:



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Thr Met Ile Thr Asn Ser His Val  
1 5

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Lys Ser Asn Asn Ala Leu Ile Val Ile Leu Gly Thr Val Thr Leu  
1 5 10 15  
Asp Ala Val Gly Ile Gly Leu Val Met Pro Val Leu Pro Gly Leu Leu  
20 25 30  
Arg Asp Ile Arg Leu Met Arg Glu Arg Asp Gly Arg Asn His Arg Asp  
35 40 45  
Met Cys Val Leu Phe Arg Trp Ala Cys Gln Asp Asn Phe Trp Ser Gly  
50 55 60  
Asn Val Leu Ser Pro Ala Lys Leu Thr Pro His Pro Pro Val Asp Asn  
65 70 75 80

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Cys Gly Ile Val Ser Gly  
1 5

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 237 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met	His	Met	Lys	Asn	Ile	Lys	Lys	Asn	Gln	Val	Met	Asn	Leu	Gly	Pro
1				5					10					15	
Asn	Ser	Lys	Leu	Leu	Lys	Glu	Tyr	Lys	Ser	Gln	Leu	Ile	Glu	Leu	Asn
			20					25					30		
Ile	Glu	Gln	Phe	Glu	Ala	Gly	Ile	Gly	Leu	Ile	Leu	Gly	Asp	Ala	Tyr
		35					40					45			
Ile	Arg	Ser	Arg	Asp	Glu	Gly	Lys	Thr	Tyr	Cys	Met	Gln	Phe	Glu	Trp
	50					55					60				
Lys	Asn	Lys	Ala	Tyr	Met	Asp	His	Val	Cys	Leu	Leu	Tyr	Asp	Gln	Trp
65					70					75					80
Val	Leu	Ser	Pro	Pro	His	Lys	Lys	Glu	Arg	Val	Asn	His	Leu	Gly	Asn
				85					90					95	
Leu	Val	Ile	Thr	Trp	Gly	Ala	Gln	Thr	Phe	Lys	His	Gln	Ala	Phe	Asn
			100					105					110		
Lys	Leu	Ala	Asn	Leu	Phe	Ile	Val	Asn	Asn	Lys	Lys	Thr	Ile	Pro	Asn
		115					120					125			
Asn	Leu	Val	Glu	Asn	Tyr	Leu	Thr	Pro	Met	Ser	Leu	Ala	Tyr	Trp	Phe
		130					135					140			
Met	Asp	Asp	Gly	Gly	Lys	Trp	Asp	Tyr	Asn	Lys	Asn	Ser	Thr	Asn	Lys
145					150					155					160
Ser	Ile	Val	Leu	Asn	Thr	Gln	Ser	Phe	Thr	Phe	Glu	Glu	Val	Glu	Tyr
				165					170					175	
Leu	Val	Lys	Gly	Leu	Arg	Asn	Lys	Phe	Gln	Leu	Asn	Cys	Tyr	Val	Lys
			180					185					190		
Ile	Asn	Lys	Asn	Lys	Pro	Ile	Ile	Tyr	Ile	Asp	Ser	Met	Ser	Tyr	Leu
		195					200					205			
Ile	Phe	Tyr	Asn	Leu	Ile	Lys	Pro	Tyr	Leu	Ile	Pro	Gln	Met	Met	Tyr
	210					215					220				
Lys	Leu	Pro	Asn	Thr	Ile	Ser	Ser	Glu	Thr	Phe	Leu	Lys			
225					230					235					

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CGCTAGGGAT AACAGGGTAA TATAGC

26

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GCGATCCCTA TTGTCCCATT ATATCG

26

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TTCTCATGAT TAGCTCTAAT CCATGG

26

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AAGAGTACTA ATCGAGATTA GGTACC

26

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CTTTGGTCAT CCAGAAGTAT ATATTT

26

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GAAACCGTA GGTCTTCATA TATAAA

26

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TAACGGTCCT AAGGTAGCGA AATTCA

26

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ATTGCCAGGA TTCCATCGCT TTAAGT

26

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TGACTCTCTT AAGGTAGCCA AATGCC

26

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ACTGAGAGAA TTCCATCGGT TTACGG

26

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CGAGGTTTTG GTAACATTTT ATTACC

26

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CCTCCAAAAC CATTGATAAA TAATGG

26

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGGTTCAAAA CGTCGTGAGA CAGTTT

26

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CCCAAGTTTT GCAGCACTCT GTCAAA

26

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GATGCTGTAG GCATAGGCTT GGTTAT

26

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

002210759466

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CTACGACATC CGTATCCGAA CCAATA

26

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CTTTCGCAA CAGTATAATT TTATAA

26

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GAAAGGCGTT GTCATATTAA AATATT

26

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

ACCATGGGGT CAAATGTCTT TCTGGG

26

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

TGGTACCCCA GTTTACAGAA AGACCC

26

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GTGCCTGAAT GATATTTATT ACCTTT

26

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

GTGCCTGAAT GATATTTATT ACCTTT

26

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 39 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CAACGCTCAG TAGATGTTTT CTTGGGTCTA CCGTTTAAT

39

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GTTGCGAGTC ATCTACAAAA GAACCCAGAT GGCAAATTA

39

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CAAGCTTATG AGTATGAAGT GAACACGTTA TT

32

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GTTCGAATAC TCATACTTCA CTTGTGCAAT AA

32

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GCTATTCGTT TTTATGTATC TTTTGCGTGT AGCTTTAA

38

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 38 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

CGATAAGCAA AAATACATAG AAAACGCACA TGGAAATT 38

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 80 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

CCAAGCTCGA ATTCGCATGC TCTAGAGCTC GGTACCCGGG ATCCTGCAGT CGACGCTAGG 60

GATAACAGGG TAATACAGAT 80

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 80 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

GGTTCGAGCT TAAGCGTACG AGATCTCGAG CCATGGGCCC TAGGACGTCA GCTGCGATCC 60

CTATTGTCCC ATTATGTCTA 80

(2) INFORMATION FOR SEQ ID NO:47:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 80 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear



(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

ATCAGATCTA AGCTTGCATG CCTGCAGGTC GACTCTAGAG GATCCCCGGG TACCGAGCTC 60

GAATTCAGTG GCCGTCGTTT 80

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

TAGTCTAGAT TCGAACGTAC GGACGTCCAG CTGAGATCTC CTAGGGGCCC ATGGCTCGAG 60

CTTAAGTGAC CGGCAGCAAA 80

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

TACAACGTCG TGAAGGGAA AACCTGGCG TTACCCAACT TAATCGCCTT GCAGCACATC 60

CCCCTTTCGC CAGCTGGCGT 80

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

ATGTTGCAGC ACTGACCCTT TTGGGACCGC AATGGGTGTA ATTAGCGGAA CGTCGTGTAG 60

GGGGAAAGCG GTCGACCGCA 80

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

TAGGGATAAC AGGGTAAT 18

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

ATCCCTATTG TCCCATTA 18